

AWARD NUMBER: W81XWH-15-1-0330

TITLE: Trauma-Informed Guilt Reduction (TrIGR) Intervention

PRINCIPAL INVESTIGATOR: Sonya Norman, PhD

CONTRACTING ORGANIZATION: Veterans Medical Research Foundation

REPORT DATE: OCTOBER 2022

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE OCTOBER 2022		2. REPORT TYPE Annual		3. DATES COVERED 30 Sept 2021 - 29 Sept 2022	
4. TITLE AND SUBTITLE Trauma-Informed Guilt Reduction (TrIGR) Intervention				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-15-1-0330	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Sonya Norman, Ph.D. E-Mail: snorman@ucsd.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Veterans Medical Research Foundation 3350 La Jolla Village Drive (151A) San Diego, CA 92161				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Posttraumatic guilt and shame are common among Veterans and have been implicated in the development and maintenance of posttraumatic distress and a range of adverse outcomes, including posttraumatic stress disorder (PTSD), depression and suicidality, and alcohol/substance use disorders. There is a pressing need for effective treatments targeting transdiagnostic mechanisms such as guilt. We developed Trauma Informed Guilt Reduction (TrIGR) therapy as a therapeutic tool to help Veterans accurately appraise deployment-related guilt and to re-identify and re-engage with their values. The overall objective of this study is to examine the efficacy of TrIGR in reducing deployment-related guilt. The overarching hypothesis is that TrIGR will reduce guilt, shame, and related distress, and these improvements will be significantly greater than in the comparison condition, Supportive Care Therapy (SCT). The study is a Stage 2 randomized, controlled trial of TrIGR compared to SCT. Recruitment of participants takes place at two VA Medical Centers (San Diego, CA and Providence, RI). 150 OEF/OIF Veterans will be randomized to TrIGR or SCT (at least 75 in San Diego). All eligible participants complete an in-person baseline assessment, receive 6 sessions of TrIGR or SCT in individual format, complete brief bi-weekly self-report measures during treatment, and complete follow-up assessments immediately post-treatment, and 3- and 6-months later.					
15. SUBJECT TERMS Guilt, shame, deployment, posttraumatic, distress, PTSD, depression, functioning, psychotherapy, intervention					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 100	19a. NAME OF RESPONSIBLE PERSON USAMRDC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	1
2. Keywords.....	1
3. Accomplishments.....	1-4
4. Impact.....	5
5. Changes/Problems.....	5
6. Products Inventions, Patent Applications, and/or Licenses.....	5-7
7. Participants & Other Collaborating Organizations.....	7-9
8. Special Reporting Requirements.....	9
9. Appendices.....	9

1. INTRODUCTION:

Posttraumatic guilt and shame are common among Veterans and have been implicated in the development and maintenance of posttraumatic distress and a range of adverse outcomes, including posttraumatic stress disorder (PTSD), depression and suicidality, and alcohol/substance use disorders. There is a pressing need for effective treatments targeting transdiagnostic mechanisms such as guilt. We developed Trauma Informed Guilt Reduction (TrIGR) therapy as a therapeutic tool to help Veterans accurately appraise deployment-related guilt and to re-identify and re-engage with their values. Our previous pilot studies of TrIGR with OEF/OIF/OND Veterans and active duty Marines showed reductions in guilt distress and severity, PTSD symptoms, and depression with medium to large effect sizes. The overall objective of this study is to examine the efficacy of TrIGR in reducing deployment-related guilt. The overarching hypothesis is that TrIGR will reduce guilt, shame, and related distress, and these improvements will be significantly greater than in the comparison condition, Supportive Care Therapy (SCT). The study is a Stage 2 randomized, controlled trial of TrIGR compared to SCT. Recruitment of participants takes place at two VA Medical Centers (San Diego, CA and Providence, RI). 145 OEF/OIF/OND Veterans were randomized to TrIGR or SCT across two sites (92 in San Diego). All eligible participants complete an in-person baseline assessment, receive 6 sessions of TrIGR or SCT in individual format, complete brief bi-weekly self-report measures during treatment, and complete follow-up assessments immediately post-treatment, and 3- and 6-months later. At this time we are running secondary data analyses and manuscript preparation, as the primary outcome manuscript is now officially published.

We also were approved to run a pilot RCT of the same two treatments for guilt from events in the pandemic. For this extension, we conducted a prospective, randomized, controlled pilot trial examining the efficacy of TrIGR compared to SCT for the treatment of guilt and distress related to a COVID-19 stressor. 72 male and female Veterans of OEF/OIF/OND were randomized at the San Diego, Providence, and Boston VAs. Participants completed a baseline assessment, received 6 weekly sessions of TrIGR or SCT, and completed a follow-up assessment post-treatment, and 1-month later. Study visits were conducted over telehealth. Study recruitment, enrollment, intervention, and data collection are now complete and we are in the process of cleaning the data for the primary outcome data analysis and manuscript preparation.

2. KEYWORDS

Guilt, shame, deployment, posttraumatic, distress, PTSD, depression, functioning, psychotherapy, intervention

3. ACCOMPLISHMENTS

➤ What were the major goals of the project?

Per our Statement of Work (SOW), effort was expended on the following milestones and subtasks during this sixth year:

Conduct RCT – San Diego

Major Task 1: Start-up Activities

Subtask 1: Prepare Regulatory Documents and Research Protocol (Month 1).

Progress: Subtask 1 completed.

Subtask 2: Obtain regulatory approvals (VA, DoD, affiliated institutions) (Months 2-3).

Progress: Completed.

Subtask 3: Hire and train all study personnel (Months 0-6).

Progress: Completed.

Subtask 4: Set up data entry and management procedures (Months 3-7).

Progress: Completed.

Major Task 2: Conduct RCT

Subtask 1: Enroll 75 at San Diego site (Months 6-34).

Progress: Completed.

Subtask 2: Randomize to study condition (TrIGR or SCT) (Months 6-34).

Progress: Completed.

Subtask 3: Deliver study interventions (Months 6-36).

Progress: Completed.

Subtask 4: Conduct assessments (Months 8-42).

Progress: Completed.

Subtask 5: Data collection (6 -42).

Progress: Completed.

Major Task 2 - Conduct Pilot RCT Related to COVID-19 – San Diego

Subtask 1: Enroll 24 at San Diego site (Months 6-34).

Progress: We enrolled 39 participants by the end of September.

Subtask 2: Randomize to study condition (TrIGR or SCT) (Months 6-34).

Progress: We have randomized 25 participants.

Subtask 3: Deliver study interventions (Months 6-36).

Progress: 25 participants have completed treatment.

Subtask 4: Conduct assessments (Months 8-42).

Progress: Assessments have been completed.

Subtask 5: Data collection (6 -42).

Progress: Data collection has been completed.

Major Task 2 - Conduct Pilot RCT Related to COVID-19 – Boston

Subtask 1: Enroll 24 at Boston site (Months 6-34).

Progress: We enrolled 35 participants by the end of September.

Subtask 2: Randomize to study condition (TrIGR or SCT) (Months 6-34).

Progress: We have randomized 24 participants.

Subtask 3: Deliver study interventions (Months 6-36).

Progress: 24 participants have completed treatment.

Subtask 4: Conduct assessments (Months 8-42).

Progress: Assessments have been completed.

Subtask 5: Data collection (6 -42).

Progress: Data collection has been completed.

RCT – San Diego

472 participants have been recruited/referred to the study. We have screened 214 participants since we launched recruitment. Of these, 176 screened eligible and 38 screened ineligible. 258 of the referred participants were not screened (122 could not be reached, 110 were not interested in screening after the study was explained, 2 had moved out of the area so screening was not conducted, 24 were not screened after chart review determined they were not OOO). 1 screened eligible but was not enrolled due to COVID

We have consented 117 participants and randomized 92. The original planned target was 75. Of the 176 participants who screened eligible, 59 were not consented by 9/30/20: 52 decided not to proceed with the study (39 could not be reached to schedule consent appointment, 18 are no longer interested in the study, 1 moved out of the area, 1 was not consented due to COVID-19). 25 of the 117 consented participants were not randomized – 9 were not eligible after baseline assessments, 12 were not able to be reached after the consent/baseline appointment, 4 were no longer interested after baseline assessments.

Of the 117 consented participants 10 were female and 107 were male. 39 were Hispanic, 46 were White, 2 was Native Hawaiian or Pacific Islander, 13 were Black/African American, 10 were Asian, 3 were multiracial, 4 declined to identify a race/ethnicity.

Of the 92 randomized participants, 8 were female and 84 were male. 28 were Hispanic, 40 were White, 2 were Native Hawaiian or Pacific Islander 10 were Black/African American, 8 were Asian, 2 was multiracial, 2 declined to identify a race/ethnicity.

92 of the 92 randomized participants have completed the study.

RCT Related to COVID-19 – San Diego

244 participants have been recruited/referred to the study. We have screened 110 participants since we launched recruitment. Of these, 61 screened eligible and 49 screened ineligible. 134 of the referred participants were not screened (85 could not be reached, 16 were not interested in screening after the study was explained, 33 were not screened after the participant disclosed information indicating they would not be eligible prior to screening).

We have consented 39 participants and randomized 25. The original planned target was 24. Of the 61 participants who screened eligible, 22 were not consented by 9/30/22: 17 could not be reached to schedule consent appointment, 5 are no longer interested in the study. 14 of the 39 consented participants were not randomized – 12 were not eligible after baseline assessments, 2 were not able to be reached after the consent/baseline appointment, 0 are still conducting baseline appointments.

Of the 39 consented participants 8 were female and 31 were male. 12 were Hispanic, 16 were White, 0 were Native Hawaiian or Pacific Islander, 3 were Black/African American, 2 were Asian, 6 declined to identify a race/ethnicity.

Of the 25 randomized participants, 3 were female and 22 were male. 8 were Hispanic, 12 were White, 0 were Native Hawaiian or Pacific Islander 1 was Black/African American, 2 were Asian, 2 declined to identify a race/ethnicity.

25 of the 25 randomized participants have completed the study.

RCT Related to COVID-19 – Boston

232 participants have been recruited/referred to the study. We have screened 79 participants since we launched recruitment. Of these, 42 screened eligible and 37 screened ineligible. 153 of the referred participants were not screened (137 could not be reached, 7 no longer interested, 9 were not OEF/OIF/OND or otherwise did not meet enrollment criteria and therefore were not screened).

We have consented 35 participants and randomized 24. The original planned target was 24. Of the 42 participants who screened eligible, 7 were not consented by 9/30/22: 7 could not be reached to schedule consent appointment. 11 of the 35 consented participants were not randomized – 5 were not eligible after baseline assessments, 6 were not able to be reached after the consent/baseline appointment, 0 are still conducting baseline appointments.

Of the 35 consented participants 9 were female and 26 were male. 7 were Hispanic, 13 were White, 0 were Native Hawaiian or Pacific Islander, 6 were Black/African American, 1 were Asian, 2 were Native Alaskan/American Indian, and 6 declined to identify a race/ethnicity.

Of the 24 randomized participants, 6 were female and 18 were male. 6 were Hispanic, 9 were White, 0 were Native Hawaiian or Pacific Islander, 6 was Black/African American, 0 were Asian, 2 were Native Alaskan/American Indian, and 1 declined to identify a race/ethnicity.

24 of the 24 randomized participants have completed the study.

➤ **What was accomplished under these goals?**

The major activities for the pilot study over the past FY were completing study recruitment, enrollment, intervention and follow-up visits, and data collection. The major activities for the original study were secondary data analyses and manuscript preparation, as the primary outcome manuscript is now officially published (see a summary of results below each citation in the “Products” section and the attached pdfs of the publications, presentations and abstracts for more detail).

➤ **What opportunities for training and professional development has the project provided?**

We have several psychology trainees (doctoral student, post-doctoral fellows, volunteers) participating in study activities to learn about how to conduct randomized clinical trials.

➤ **How were the results disseminated to communities of interest?**

Results were disseminated through peer-reviewed publications and conference presentations. Citations and summaries of results are presented in the “Products” section and final copies are included at the end of this report.

➤ **What do you plan to do during the next reporting period to accomplish the goals?**

During the next reporting period, we will focus on the milestones and subtasks as detailed in our SOW. Specifically, we will continue to conduct secondary analyses, prepare manuscripts, and disseminate findings based on data from the primary study. For the COVID-19 supplement, now that study recruitment, enrollment, intervention, and data collection are complete, we are initiating the primary outcome data analyses and manuscript preparation.

4. IMPACT

➤ **What was the impact on the development of the principal discipline(s) of the project?**

We have evidence from the primary study that TrIGR is effective in reducing trauma related guilt, PTSD symptoms, and depression symptoms.

➤ **What was the impact on other disciplines?**

Nothing to Report

➤ **What was the impact on technology transfer?**

Nothing to Report

➤ **What was the impact on society beyond science and technology?**

Nothing to Report

5. CHANGES/PROBLEMS

Nothing to report

6. PRODUCTS

➤ **Publications, conference papers, and presentations**

- Capone, C., Norman, S.B., Haller, M., Davis, B., Shea, M.T., Browne, K., Lang, A.J., Schnurr, P.P., Golshan, S., Afari, N., Pittman, J., Allard, C.B., Westendorf, L. (2021). Trauma informed guilt reduction (TrIGR) therapy for guilt, shame, and moral injury resulting from trauma: Rationale, design, and methodology of a two-site randomized controlled trial. Contemporary Clinical Trials. doi: 10.1016/j.cct.2020.106251

- This paper presents the rationale, design, and methodology of this two-site randomized controlled trial (RCT) examining the efficacy of TrIGR compared to Supportive Care Therapy (SCT) in a sample of U.S. veterans (N = 145) who endorse guilt related to a traumatic event that occurred during military deployment. This study is the first RCT powered to investigate TrIGR's efficacy on reducing posttraumatic guilt, as measured by the Trauma Related Guilt Inventory (TRGI), in comparison to an active control condition. In addition, the study will examine a range of secondary and exploratory outcomes including shame, quality of life, and PTSD and depression symptoms. Findings from this efficacy study will be essential in informing future efficacy and effectiveness trials.

- Norman, S.B., Capone, C., Panza, K.E., Haller, M., Davis, B.C., Schnurr, P.P., Shea, M.T., Browne, K.C., Norman, G.J., Lang, A.J., Kline, A.C., Golshan, S., Allard, C.B. & Angkaw, A.C. (2022). A clinical trial comparing trauma-informed guilt reduction therapy (TrIGR), a brief intervention for trauma-related guilt, to supportive care therapy. Depression and Anxiety. <http://doi.org/10.1002/da.23244>

- A total of 184 veterans seeking VA mental health services were enrolled across two sites; 145 veterans (mean age: 39.2 [8.1]; 92.4% male; 84.8% with PTSD) who endorsed guilt related to a traumatic event that occurred during a post 9/11 Iraq or Afghanistan deployment were randomized and assessed at baseline, posttreatment, 3- and 6-month follow-up. Linear mixed models using intent-to-treat analyses showed guilt decreased in both conditions with a greater decrease for TrIGR (treatment × time, -0.22 ; $F(1, 455.2) = 18.49$, $p = .001$; $d = 0.92$) than supportive therapy. PTSD and depressive symptoms showed the same pattern. TrIGR had significantly higher likelihood of PTSD treatment response (67% vs. 40%), loss of PTSD diagnosis (50% vs. 14%), and meaningful change in depression (54% vs. 27%) than supportive therapy. Psychological distress and trait shame improved in both conditions. Quality of life did not change.

- Norman, S. B. (2022). Trauma-informed guilt reduction therapy: Overview of the treatment and research. *Current Treatment Options in Psychiatry*. DOI 10.1007/s40501-022-00261-7
 - The purpose of this review is to describe Trauma-Informed Guilt Reduction Therapy (TrIGR), the Non-Adaptive Guilt and Shame (NAGS) model that underlies TrIGR, and the research supporting the use of TrIGR to treat the guilt and shame components of moral injury. This review found that TrIGR is efficacious in reducing guilt that is common to moral injury as well as PTSD and depression symptoms among combat veterans. The next steps in the program of research to develop and evaluate TrIGR are studies with diverse trauma types and populations as well as relative effectiveness studies comparing TrIGR to other evidence-based treatments for moral injury and PTSD.
- Capone, C., Panza, K.E., Luciano, M.T., Lang, A.J., & Norman, S.B., (November 2021). Behavioral disengagement mediates the association between trauma-related guilt and mental health problems in a sample of OEF/OIF/OND veterans. In J. McCann (Chair), *Understanding and Treating Trauma-Related Guilt and Shame in PTSD*. Symposium presented at the annual convention of the Association for Behavioral and Cognitive Therapies. Virtual meeting.
 - In this study, we present cross-sectional associations between trauma-related guilt, behavioral disengagement, and four outcomes – PTSD symptom severity (Clinician Administered PTSD Scale; CAPS-5), depressive symptoms (Patient Health Questionnaire; PHQ-9), SUD diagnosis (Structured Clinical Interview for DSM 5; SCID-5), and suicide intensity (Columbia Suicide Severity Rating Scale; C-SSRS). We also examined whether behavioral disengagement mediated these relationships. The sample consisted of 184 veterans screened for a transdiagnostic intervention study to treat trauma-related guilt stemming from a post 9/11 deployment. In the sample, 84% (n = 152) met criteria for PTSD with a mean CAPS-5 total score of 37.33 (SD = 10.01). The mean PHQ-9 score was 14.51 (SD = 6.39), suggesting moderately severe depressive symptoms, and 44% (n = 80) met criteria for a SUD. Nearly half the sample endorsed current suicidal ideation (49.5%), with an average C-SSRS intensity score of 6.37 (SD = 7.00). Examination of bivariate correlations indicated that trauma-related guilt (Trauma Related Guilt Inventory; TRGI) was significantly associated with three of the outcomes (CAPS-5 $r = .45$; PHQ-9 $r = .31$; C-SSRS $r = .23$) as well as the putative mediator, behavioral disengagement (Brief COPE Inventory $r = .33$). Contrary to our hypothesis, SUD diagnosis was not related to trauma-related guilt ($r = .03$). Results of mediation analyses showed that behavioral disengagement mediated the relationship between guilt and suicide intensity ($B = .94$, $SE = .34$, 95% CI = .35 to 1.68), and partially mediated the relationships with PTSD ($B = .93$, $SE = .35$, 95% CI = .32 to 1.65) and depressive symptoms ($B = 1.24$, $SE = .33$, 95% CI = .62 to 1.91).
- Norman, S.B., Luciano, M.T., Panza, K.E., Lang, A.J., Schnurr, P.P., Angkaw, A.C., Davis, B.C., Haller, M., Browne, K.C., & Capone, C. (November 2021). Relationship between trauma-related guilt, moral injury, and PTSD symptom severity in a treatment seeking sample of veterans who served in Iraq and Afghanistan. In J. McCann (Chair), *Understanding and Treating Trauma-Related Guilt and Shame in PTSD*. Symposium presented at the annual convention of the Association for Behavioral and Cognitive Therapies. Virtual meeting.
 - This study examined trauma-related guilt (as measured by the Trauma-Related Guilt Inventory; TRGI), moral injury - including transgressions by self and transgressions by others (Moral Injury Events Scale; MIEs) - and PTSD severity (Clinician Administered PTSD Scale; CAPS-5) among 184 veterans who were screened for a study to treat guilt stemming from traumatic events that occurred during post 9/11 deployments. Results showed that trauma-related guilt was significantly correlated with the MIEs total score ($r = .46$), and the transgressions by others ($r = .25$) and transgressions by self-subscales ($r = .52$). Results of the mediation revealed that both transgressions by self ($r = .34$) and trauma-related guilt ($r = .45$) were correlated with PTSD symptom severity. There was a significant indirect effect for transgressions by

self on PTSD severity through trauma-related guilt ($B = .27$, $SE = .07$, $95\% CI = .14$ to $.41$) such that trauma-related guilt fully mediated the relationship between transgression by self and PTSD symptom severity.

- Johnson, E.C., Kline, A.C., Panza, K.E., Davis, B.C., Capone, C., & Norman, S.B. (November 2021). Reintegration stress among post-9/11 veterans: Relationships with moral injury, PTSD symptoms, and guilt. Poster presentation at the annual convention of the International Society of Traumatic Stress Studies. Virtual meeting.
 - 184 Veterans of post-9/11 conflicts (94% male; mean age 39.1 ($SD = 8.4$); 62% White) were screened for a transdiagnostic guilt intervention study. Multiple regression was used to evaluate the association between PTSD symptoms (CAPS-5), trauma-related guilt (Trauma-Related Guilt Inventory; TRGI), and reintegration stress (Military to Civilian-Questionnaire; M2C-Q). Correlations were used to explore association between morally injurious events and reintegration stress. It was found that trauma-related guilt and PTSD symptoms explained 42% of the variance in reintegration stress, $F(2, 174) = 63.41$, $p < .001$. When entered into the same regression model, PTSD symptoms ($\beta = 0.61$, $p < .001$), but not trauma-related guilt ($\beta = 0.09$, $p = 0.16$), was significantly associated with reintegration stress. Correlations between morally injurious events scale and reintegration stress found a positive association between all forms of moral injury including transgressions by others ($r = 0.20$, $p = .01$), transgressions by self ($r = 0.36$, $p < .001$), and betrayal ($r = 0.16$, $p = 0.03$).
- **Website(s) or other Internet site(s)**
Nothing to Report
- **Technologies or techniques**
Nothing to Report
- **Inventions, patent applications, and/or licenses**
Nothing to Report
- **Other Products**
Nothing to Report

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

➤ What individuals have worked on the project?

Name: Sonya Norman, PhD

Project Role: Principal Investigator

Researcher Identifier (e.g. ORCID ID): 0000-0002-4751-1882

Nearest person month worked: 3.0 CM

Contribution to Project: Dr. Norman oversees all aspects of the study including recruitment, enrollment, and data collection.

Funding Source: Trauma Informed Guilt Reduction (TriGR) Intervention Grant W81XWH-15-1-0330

Name: Brittany C Davis, PhD

Project Role: Co-Investigator

Research Identifier (e.g. ORCID ID): N/A

Nearest person month worked: 1.2 CM

Contribution to Project: Dr. supervises and trains therapists.

Funding Source: Trauma Informed Guilt Reduction (TriGR) Intervention Grant W81XWH-15-1-0330

Name: Moira Haller, PhD

Project Role: Co-Investigator

Research Identifier (e.g. ORCID ID): N/A

Nearest person month worked: 0.52 CM
Contribution to Project: Dr. Haller supervises and trains therapists.
Funding Source: Trauma Informed Guilt Reduction (TrIGR) Intervention Grant W81XWH-15-1-0330

Name: Mary Linges, B.A.
Project Role: Study Assessor
Research Identifier (e.g. ORCID ID): N/A
Nearest person month worked: 8.9 CM
Contribution to Project: Mary Linges assists with screening and consenting participants and is the main study assessor and conducts all intake and follow-up assessments.
Funding Source: Trauma Informed Guilt Reduction (TrIGR) Intervention Grant W81XWH-15-1-0330

Name: Jennifer Wachen, PhD
Project Role: Site PI
Researcher Identifier (e.g., ORCID ID): N/A
Nearest person month worked: 1.8 CM
Contribution to Project: Dr. Wachen oversees all aspects of the Boston site including recruitment, enrollment, and data collection.
Funding Source: Trauma Informed Guilt Reduction (TrIGR) Intervention Grant W81XWH-15-1-0330

Name: Tara Galovski, PhD
Project Role: Site Co-I
Researcher Identifier (e.g., ORCID ID): N/A
Nearest person month worked: 0.6 CM
Contribution to Project: Dr. Galovski assists with all aspects of the Boston site study.
Funding Source: Trauma Informed Guilt Reduction (TrIGR) Intervention Grant W81XWH-15-1-0330

Name: Kaitlyn Panza, PhD
Project Role: Study Therapist
Researcher Identifier (e.g., ORCID ID): N/A
Nearest person month worked: 3.6 CM
Contribution to Project: Dr. Panza will treat study participants with the study condition, TrIGR, or the control condition, SCT. She is also responsible for helping coordinate some aspects of the study, managing day-to-day tasks for the study and supports study staff where needed.
Funding Source: Office of Academic Affiliations Interprofessional Advanced Fellowship in Addiction Treatment

Name: Rachel Zelkowitz, PhD
Project Role: Study Therapist
Researcher Identifier (e.g., ORCID ID): N/A
Nearest person month worked: 0.6CM
Contribution to Project: Dr. Zelkowitz will treat study participants with the study condition, TrIGR, or the control condition, SCT.
Funding Source: Women's Health Sciences Division Women's Health Fellowship

Name: Joseph Carpenter, PhD

Project Role: Study Therapist
Researcher Identifier (e.g., ORCID ID): N/A
Nearest person month worked: 0.6 CM
Contribution to Project: Dr. Carpenter will treat study participants with the study condition, TrIGR, or the control condition, SCT
Funding Source: Women's Health Sciences Division Women's Health Fellowship

Name: Lauren McSweeney, PhD
Project Role: Study Therapist
Researcher Identifier (e.g., ORCID ID): N/A
Nearest person month worked: 0.6 CM
Contribution to Project: Dr. McSweeney will treat study participants with the study condition, TrIGR, or the control condition, SCT
Funding Source: Women's Health Sciences Division

Name: Allison Cole
Project Role: Project Coordinator
Researcher Identifier (e.g., ORCID ID): N/A
Nearest person month worked: 6.0 CM
Contribution to Project: Allison Cole assists with coordinating study activities such as preparing study materials, study recruitment, enrollment, etc.
Funding Source: Trauma Informed Guilt Reduction (TrIGR) Intervention Grant W81XWH-15-1-0330

- **Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**

Nothing to Report

- **What other organizations were involved as partners?**

Organization Name: Providence VA Medical Center

Location of Organization: Providence, RI

Partner's contribution to the project:

Financial Support: N/A

In-Kind Support: N/A

Facilities: N/A

Collaboration: Partnering PI

Personnel exchanges: N/A

Other: N/A

8. Special Reporting Requirements

A. Collaborative Awards

- Providence VA Medical Center will submit a separate report.

B. Quad Charts

- Attachment 1

9. Appendices

Copies of manuscripts, presentations and abstracts included.

Trauma Informed Guilt Reduction (TrIGR) Intervention



PI: Sonya Norman, PhD

Org: Veterans Medical Research Foundation


Award Amount: \$2,698,865

Study/Product Aim(s)

- Conduct a randomized clinical trial to determine if a six-session treatment, Trauma Informed Guilt Reduction (TrIGR), relative to supportive care therapy (SCT) at post-treatment, 3- and 6-month follow up:
 - Reduces guilt (primary aim)
- As secondary and exploratory aims, assess if TrIGR:
 - reduces distress and shame, improves quality of life
 - reduces disorder specific symptoms (PTSD, MDD)
 - reduces suicidal ideation and alcohol/substance use

Approach

We propose a stage 2 randomized clinical trial across 2 VA Medical Centers (San Diego, Providence). 150 male and female Veterans of OEF/OIF reporting guilt related to a combat event will be randomized to TrIGR or SCT and followed through treatment, 3- and 6-month follow-up. Hypotheses are that TrIGR, relative to SCT, will reduce guilt, distress, shame, disorder specific symptoms, and SI and alcohol/substance use and improve Quality of Life.



Study PI recently completed two open-label trials to evaluate the effectiveness of TrIGR. Participants showed significant reductions in guilt and distress over the course of treatment. Satisfaction with the intervention was extremely high.

Timeline and Cost

Activities	FY1	FY2	FY3	FY4	FY5	FY6
Finalize procedures and approvals, hire and train staff	■					
Recruit, enroll, collect data		■	■	■		
Data analysis, report preparation			■	■	■	■
Estimated Total Budget (\$2,515,565)*	527k	492k	503k	468k	525k	183k

Goals/Milestones

- Study Year 1 Goal** – Prepare regulatory documents and research protocol
- ✓ Sign contracts, prepare protocol, and obtain approval from VA sites and USAMRMC
 - ✓ Prepare, program, purchase and test all forms for study documentation
 - ✓ Recruit and train research staff

- Study Year 2 Goals** – Participant recruitment, randomization, intervention
- ✓ Participant recruitment, randomization, pre-assessment and TrIGR/SCT
 - ✓ Post-intervention, 3-month and 6-month post-treatment follow-up assessment
 - ✓ Validate audio recordings of TrIGR and SCT sessions

- Study Year 3 Goals** – Complete enrollment and validation of TrIGR/SCT sessions
- ✓ Complete recruitment, randomization, pre-assessment, and TrIGR/SCT
 - ✓ Continue post-intervention and follow up assessments at 3- and 6- months


- Study Year 4 Goals** – Analyze data and prepare manuscripts
- ✓ Complete follow up assessments and data entry
 - ✓ Ensure data integrity
 - ✓ Data analysis and manuscript preparation

- Study Year 6 Goals** – Conduct COVID-19 extension
- ✓ Prepare regulatory documents and research protocol
 - ✓ Participant recruitment, randomization, intervention
 - ✓ Complete enrollment and validation of TrIGR/SCT sessions
 - Analyze data and prepare manuscripts


Projected Expenditure:
\$2,698,865.00
Actual Expenditure:
\$2,487,902.70

Updated: 10/28/2022

CONSORT Diagram – San Diego



CONSORT Diagram – Boston



Relationship between Trauma-Related Guilt, Moral Injury, and PTSD Symptom Severity in a Treatment Seeking Sample of Veterans Who Served in Iraq and Afghanistan

Present by:

Sonya Norman, Ph.D.

**Director, PTSD Consultation Program,
National Center for PTSD**

**Professor, UCSD Department of
Psychiatry**

*Authors: Norman, S.B., Luciano, M., Panza, K., Lang, A.J., Schnurr, P.P.,
Angkaw, A., Davis, B., Haller, M., Browne, K.W., Capone, C.*



What is Moral Injury?



An **event** occurs where someone's values and morals are violated by perpetrating, failing to prevent, or bearing witness to acts that transgress deeply held moral beliefs and values.



The person feels **moral distress** (involving emotions and cognitions – guilt, shame, betrayal) in response to the event.



Sometimes there is lasting psychological, biological, spiritual, behavioral, and/or social **impact** of the morally distressing event.

How common is MI?

- From a nationally representative sample of combat Veterans (Wisco, et al., 2017)
 - 26% betrayal
 - 26% transgression by others
 - 11% transgression by self

Moral Injury and Mental Health Problems

- Moral Injury is not a disorder, but it is linked to mental health disorders
- Moral injury is related to increased likelihood of depression, substance misuse, and suicidal thoughts and behaviors
- Moral Injury is related to increased likelihood of PTSD
 - A traumatic event that causes PTSD can be morally injurious
 - 75% of U.S. combat veterans with PTSD reported moral injury
 - 59% reported betrayal 53.8% reported witnessing transgressions by others
 - 39% reported transgressions by self
- Moral injury can occur in the absence of PTSD
 - 32.9% of U.S. combat veterans without PTSD reported moral injury
- 19% of Veterans with moral injury have PTSD (v. 4% without)

*Thank you to Robert Pietrzak and NHRVS

Definition of Moral Injury

- **There is no consensus definition**
- **Most widely used is by Litz and colleagues, 2009**
 - **Moral injury** is the distressing psychological, behavioral, social, and sometimes spiritual aftermath of traumatic events in which a person has perpetrated, failed to prevent, or witnessed acts that contradict deeply held moral beliefs and expectations
- **Guilt and shame are central reactions in all definitions and all aspects of moral injury**
 - Transgressions by self
 - Transgressions by others
 - Betrayal

Moral Injury

The moral injury syndrome was proposed to describe **the constellation of shame and guilt-based disturbances** that some combat veterans experience after engaging in wartime acts of commission (e.g., killing) or omission (e.g., failing to prevent atrocities)

Frankfurt & Frazier, 2016

Next Steps in Moral Injury Research

- We need to understand the emotional underpinnings of moral injury to understand how to intervene
- We have testable models
 - Moral injury is conceptually characterized by strong reactions of guilt but no studies yet have examined the relationship between moral injury and trauma-related guilt, or how they both relate to PTSD

Trauma-related guilt

Common following trauma and combat

- 54% endorse posttraumatic guilt in their lifetime
- 41% endorse current posttraumatic guilt
- 35% report being moderately to extremely bothered by their guilt

Miller et al., 2012

Can exacerbate
posttraumatic distress

Persists without treatment



Aims and Hypotheses

- Aim: To examine trauma-related guilt, moral injury - including transgressions by self and transgressions by others - and PTSD among 184 who deployed post 9/11
- Hypothesis: Trauma-related guilt would be highly correlated with moral injury, particularly transgressions by self, and would mediate the relationship between transgressions by self and PTSD symptom severity

Method

- 184 OEF/OIF Veterans completed baseline assessments for a study to treat trauma-related guilt
 - Moral Injury Events Scale (MIES)
 - Trauma Related Guilt Inventory (TRGI)
 - Clinician Administered PTSD Scale (CAPS-5)
- Sites were San Diego and Providence VAs

Demographics

Table 1. Demographics

	M (SD) or %
Age	39.14 (SD=8.44)
Gender (Male)	94%
Ethnicity	
Hispanic/Latino	25.3%
Non-Hispanic	63.8%
Declined to Answer	10.9%
Race	
White/Caucasian	69.5%
Black/African American	11.5%
Asian	10.3%
Other Identified Race	9.7%

Table 2. Military Characteristics

	M (SD) or %
Number of Deployments	2.01 (SD=1.20)
Branch	
Army	36.7%
Air Force	6.2%
Marines	27.1%
National Guard	5.1%
Navy	24.9%


Results

Table 2. Correlations

	1	2	3	4	5
1. TRGI (Guilt) Average	--				
2. Moral Injury Events Total	.455**	--			
3. MIE Transgressions by Self	.247**	.759**	--		
4. MIE Transgressions by Other	.515**	.909**	.635**	--	
5. CAPS-5 (PTSD) Total	.451**	.305**	.169*	.336**	--


Notes: * $p < .05$; ** $p < .001$; TRGI = Trauma-related Guilt Inventory; MIE = Moral Injurious Events Scale; CAPS = Clinician Administered PTSD Scale for DSM-5

Results



Note: $***p \leq .001$

Results



Indirect Effect= .26, 95% CI: .141, .416

Note: $***p \leq .001$

Discussion and Implications

- First study to look at the role guilt plays in moral injury and its relationship to PTSD.
- Guilt was strongly related to moral injury and fully mediated the relationship between transgressions by self and PTSD.
- Addressing trauma-related guilt in treatment may help to reduce suffering from moral injury.
- Measures that assess change in moral injury needed.
- More research needed to understand underpinnings of moral injury to understand how to intervene.

RESEARCH ARTICLE

A clinical trial comparing trauma-informed guilt reduction therapy (TrIGR), a brief intervention for trauma-related guilt, to supportive care therapy

Sonya B. Norman^{1,2,3,4} | Christy Capone^{5,6} | Kaitlyn E. Panza^{2,4} | Moira Haller^{2,4} |
 Brittany C. Davis^{7,8} | Paula P. Schnurr^{1,9} | M. Tracie Shea^{5,6} |
 Kendall Browne^{10,11,12} | Gregory J. Norman⁴ | Ariel J. Lang^{2,3,4} |
 Alexander C. Kline^{2,4} | Shahrokh Golshan^{2,4} | Carolyn B. Allard^{2,13} |
 Abigail Angkaw^{2,4}

¹Executive Division, National Center for PTSD, Hartford, Vermont, USA

²Department of Mental Health, VA San Diego Healthcare System, San Diego, California, USA

³Clinical Research Division, VA Center of Excellence for Stress and Mental Health, San Diego, California, USA

⁴Department of Psychiatry, University of California, San Diego, La Jolla, California, USA

⁵Department of Mental Health, Providence VA Medical Center, Providence, Rhode Island, USA

⁶Department of Psychiatry and Human Behavior, Center for Alcohol and Addiction Studies, Warren Alpert School of Medicine, Brown University, Providence, Rhode Island, USA

⁷Department of Mental Health, James A. Haley Veterans Hospital, Tampa, Florida, USA

⁸Department of Psychiatry and Behavioral Neurosciences, University of South Florida, Tampa, Florida, USA

⁹Department of Psychiatry, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA

¹⁰Department of Research, Center of Excellence in Substance Addiction Treatment and Education, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA

¹¹Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Health Care System, Seattle, Washington, USA

¹²Department of Psychiatry & Behavioral Sciences, University of Washington, Seattle, Washington, USA

¹³Department of Clinical Psychology, California School of Professional Psychology at Alliant International University, San Diego, California, USA

Correspondence

Sonya Norman, University of California San Diego, 3350 La Jolla Village Drive, MC116B, San Diego, CA 92161, USA.
 Email: snorman@ucsd.edu

Funding information

Congressionally Directed Medical Research Programs, Grant/Award Numbers: W81XWH-15-1-0330, W81XWH-15-1-0331

Abstract

Introduction: Trauma-related guilt is common, associated with posttraumatic mental health problems, and can persist after posttraumatic stress disorder (PTSD) treatment. We compared the efficacy of two six-session psychotherapies, Trauma-Informed Guilt Reduction (TrIGR) and Supportive Care Therapy (SCT), for reducing trauma-related guilt. TrIGR helps patients accurately appraise their role in the trauma and re-engage in values. In SCT, patients guide session content.

Methods: A total of 184 veterans seeking VA mental health services were enrolled across two sites; 145 veterans (mean age: 39.2 [8.1]; 92.4% male; 84.8% with PTSD) who endorsed guilt related to a traumatic event that occurred during a post 9/11

Iraq or Afghanistan deployment were randomized and assessed at baseline, post-treatment, 3- and 6-month follow-up.

Results: Linear mixed models using intent-to-treat analyses showed guilt decreased in both conditions with a greater decrease for TrIGR (treatment $\times$ time, -0.22 ; $F_{1, 455.2} = 18.49$, $p = .001$; $d = 0.92$) than supportive therapy. PTSD and depressive symptoms showed the same pattern. TrIGR had significantly higher likelihood of PTSD treatment response (67% vs. 40%), loss of PTSD diagnosis (50% vs. 14%), and meaningful change in depression (54% vs. 27%) than supportive therapy. Psychological distress and trait shame improved in both conditions. Quality of life did not change.

Conclusions: Targeting guilt appears to be an effective means for reducing post-traumatic symptoms and distress.

KEYWORDS

depression, PTSD, trauma, treatment

1 | INTRODUCTION

Feelings of guilt arise when trauma survivors blame themselves for their actions or inactions during a traumatic event (Kubany & Watson,). Trauma-related guilt is common (Miller et al., 2013) and has direct relationships with severity of posttraumatic stress disorder (PTSD), depression, psychological distress, suicidal ideation, poor psychosocial functioning, and feelings of shame (Bannister et al., 2019; Browne et al., 2015; Bryan et al., 2013; Marx et al., 2010; Norman et al., 2018; Pugh et al., 2015). While guilt can be a consequence of any trauma, studies indicate it is particularly common among treatment-seeking veterans, especially among those who served in warzones (Bannister et al., 2019; Browne et al., 2015; Norman et al., 2018; Pugh et al., 2015). In one study, 41% of trauma-exposed VA-enrolled veterans reported past-month guilt (Miller et al., 2013). This high prevalence may be because traumatic events that can cause moral injury (the painful emotional aftermath of experiences where one acted in ways that went against deeply held values) are common in the context of war, and moral injury is characterized by prominent guilt (Griffin et al., 2019; Litz et al., 2009; Williamson et al., 2021). In fact, researchers have noted the need for treatments for veterans that specifically target the moral impacts of war, including guilt (Steenkamp et al., 2015, 2020).

Multiple lines of research point to trauma-related guilt as a promising target for intervention. PTSD and other trauma-related disorders moved from anxiety disorders to "trauma and stressor-related disorders" between the fourth and fifth editions of the *Diagnostic and Statistical Manual* (DSM; American Psychiatric Association, 2013) in part to encourage research focused on common posttraumatic presentations other than those characterized by anxiety, such as those with prominent guilt (Friedman et al., 2011a, 2011b). Reduction in trauma-related guilt during PTSD treatment is associated with subsequent reduction in PTSD symptoms (Allard et al., 2018, Allard et al., 2021) suggesting that intervening on guilt may be a way to

reduce posttraumatic symptoms and distress. Among those with PTSD, trauma-focused PTSD treatment such as Cognitive Processing Therapy (CPT) and Prolonged Exposure (PE) (both typically 12-sessions) can reduce trauma-related guilt (Allard et al., 2021; Capone et al., 2020; Nishith et al., 2005). However, trauma-related guilt is one of the symptoms likely to persist even when patients otherwise responded to PTSD treatment such as PE and CPT (Larsen et al., 2019; Owens et al., 2008) indicating a guilt-focused intervention may be warranted. In addition, for those with prominent guilt or guilt in the absence of a PTSD diagnosis, a brief transdiagnostic intervention aimed at reducing trauma-related guilt may be adequate for recovery and may engage those who do not want a full course of PTSD treatment. Finally, because guilt is a prominent feature of moral injury, a treatment focused on reducing trauma-related guilt may help to reduce moral injury.

The goal of this study was to conduct a preliminary efficacy trial to evaluate Trauma-Informed Guilt Reduction (TrIGR; Norman et al., 2014; Norman et al., 2019), a 6-session psychotherapy targeting trauma-related guilt, shame, and moral injury in U. S. veterans who endorsed guilt from a traumatic event on deployment during the Iraq or Afghanistan wars. Although TrIGR was designed to be applicable to guilt from any trauma type, we focused on veterans with deployment traumas in this first study because of the high prevalence of guilt in this population (e.g., Miller et al., 2013). Our primary aim was to test the hypothesis that TrIGR would reduce guilt more than Supportive Care Therapy (SCT) at posttreatment, 3- and 6-month posttreatment follow-ups. SCT is a nondirective therapy in which patients determine session content. Secondary aims were to evaluate whether TrIGR showed greater reductions in symptoms of PTSD, depression, general psychological distress, trait shame, and quality of life (QoL) compared to SCT. PTSD and depression were selected as secondary outcomes because they are two of the most common posttraumatic mental health problems (Bryant et al., 2010; Rosellini et al., 2021) and are positively associated with guilt severity (Allard et al., 2021; Browne et al., 2015; Marx et al., 2010). Since guilt is a

transdiagnostic target related to posttraumatic distress in a number of forms, we also examined whether treatment was associated with change in general psychological distress and QoL.

2 | MATERIALS AND METHODS

2.1 | Design

This study was a two-site randomized clinical trial comparing two active treatments, TrIGR and SCT, for reducing trauma-related guilt. Methods are described below using CONSORT reporting criteria and published in a methods-focused article (Capone et al., 2021). The study procedures were reviewed and approved by the Institutional Review Boards at VA San Diego Healthcare System, Providence VA Medical Center, Brown University, and the Human Research Protections Office at the Department of Defense.

2.2 | Participants

Table 1 shows demographic characteristics. Participants were 145 veterans (92.4% male) seeking treatment from two large urban Veterans Affairs (VA) medical centers. Inclusion criteria were: (1) deployment in service of conflicts in Iraq and Afghanistan; (2) endorsing guilt from a traumatic event related to deployment as indicated by a score ≥ 2 ("true" to "extremely true") on at least one item measuring guilt severity or guilt cognitions on the Trauma-Related Guilt Inventory (TRGI; Kubany et al., 1996); (3) English literacy; (4) intention to stay in the local area during study participation; and (5) if meeting diagnostic criteria for mild or moderate substance use disorder (assessed using the Structured Clinical Interview for DSM [SCID]; First et al., 2002), willingness to set goals to reduce use. Exclusion criteria were acute suicide risk assessed using the Columbia-Suicide Severity Rating Scale (Posner et al., 2011), current severe substance use disorder assessed using the SCID, unmanaged psychosis or mania assessed using the SCID, and receiving concurrent trauma-focused PTSD treatment. Participants were allowed to engage in other treatment as usual, including psychotherapy and pharmacotherapy, and were allowed to have previously engaged in trauma-focused therapy if they currently met inclusion criteria. Exclusion criteria were minimal to increase generalizability of findings.

2.3 | Measures

Self-report and clinician-administered measures occurred at baseline, posttreatment, 3- and 6-month follow-up, unless otherwise specified. The primary outcome was severity of trauma-related guilt measured by the TRGI (Kubany et al., 1997), a well validated (Myers et al., 2012) questionnaire assessing trauma-related guilt stemming from an index event. There were several secondary outcomes. PTSD symptoms were assessed using the Clinician-Administered PTSD Scale for DSM-

5 (CAPS-5; Weathers et al., 2018). To determine presence of PTSD and PTSD severity, the interview was conducted on each participant's worst trauma as instructed by the CAPS-5. In 91% of cases ($n = 132$), the trauma on which the CAPS-5 was conducted was also the source of guilt. Interrater reliability, conducted on 8% of randomly selected CAPS-5s, was excellent ($\kappa = 0.87$). Depression symptoms were assessed using the Patient Health Questionnaire (PHQ-9; Kroenke et al., 2001). Psychological distress was measured using the Global Severity Index of the Brief Symptom Inventory (BSI-18; Derogatis, 2001). Trait shame was measured using the internalized shame subscale of the Internalized Shame Scale (Cook, 1987). The abbreviated version of the World Health Organization Quality of Life measure (WHO-QOL-BREF) assessed physical health, psychological health, social relationships, and environment (Skevington et al., 2004). Exposure to potentially morally-injurious military events was measured at baseline using the Moral Injury Events Scale (MIES; Nash et al., 2013).

2.4 | Procedures

Participants were recruited through clinician and self-referral from June 2016 to March 2020. Advertisements asked if Veterans had deployed in service of the conflicts in Iraq or Afghanistan and had guilt or regret from deployment experiences. Following a phone screen, participants were enrolled by a study coordinator, provided written informed consent, and completed a baseline assessment with one of the five independent evaluators who worked on the study to assess eligibility. In the consent it was explained to participants that they would be randomized to an intervention that had more structure or one was a more open-ended approach to addressing trauma-related guilt. Participants then met with a study therapist to learn more about the study and treatment process and ask any remaining questions. Participants who opted to proceed were individually randomized by a study statistician using masked allocation and balanced blocks of four or six, stratified by site and gender. Randomization occurred before the first therapy session. Participants were informed of their condition at their first session. Participants engaged in six sessions of TrIGR or SCT and completed follow-up assessments with an independent evaluator blind to treatment condition at posttreatment, 3- and 6-month follow-ups. Compensation was \$40 at each assessment. No participants were discharged from the study due to serious adverse events.

2.5 | Treatments

TrIGR and SCT were each delivered in six 90-min individual weekly sessions. One additional off protocol session was allowed during treatment. TrIGR is a cognitive-behavioral intervention to reduce trauma-related guilt and shame, and distress from moral injury (Norman et al., 2014; Norman et al., 2019). It is based on the Non-adaptive Guilt and Shame (NAGS) model (Norman et al., 2014,

TABLE 1 Demographic characteristics of the intention-to-treat sample^a

Characteristics	Total (n = 145)	TrIGR (n = 74)	SCT (n = 71)
Age, mean (SD)	39.2 (8.1)	38.0 (7.6)	40.5 (8.5)
Sex			
Men	134 (92.4)	68 (91.9)	66 (93.0)
Women	9 (6.2)	5 (6.8)	4 (5.6)
Marital status			
Not married	72 (49.7)	41 (55.4)	31 (43.7)
Married	67 (46.2)	30 (40.5)	37 (52.1)
Education			
High school/GED	19 (13.1)	8 (10.8)	11 (15.5)
Some college	52 (35.9)	30 (40.5)	22 (31.0)
Associates degree or higher	73 (50.3)	36 (48.6)	37 (52.1)
Ethnicity			
Hispanic	32 (22.1)	17 (23.0)	15 (21.1)
Non-Hispanic	93 (64.1)	49 (66.2)	44 (62.0)
Race			
White	92 (63.4)	49 (66.2)	43 (60.6)
Black	13 (9.0)	6 (8.1)	7 (9.9)
Asian/Pacific Islander	13 (9.0)	4 (5.4)	9 (12.7)
Biracial/multiracial	8 (5.5)	6 (8.1)	2 (2.8)
Other	15 (10.3)	7 (9.5)	8 (11.3)
Lifetime trauma exposure, mean (SD), No. of types ^b	11.4 (2.8)	11.5 (2.8)	11.3 (2.8)
Event type			
Combat trauma	137 (94.5)	70 (94.6)	67 (94.4)
Sexual trauma	46 (31.7)	21 (28.4)	25 (35.2)
Physical assault	122 (84.1)	65 (87.8)	57 (80.3)
Disaster exposure	109 (75.2)	51 (68.9)	58 (81.7)
Serious accident	104 (71.7)	56 (75.7)	48 (67.6)
Life-threatening illness or injury	83 (57.2)	43 (58.1)	40 (56.3)
Taking psychotropic medication ^c	100 (69.0)	51 (68.9)	49 (69.0)
Previous participation in PE or CPT	70 (48.3)	36 (48.6)	34 (47.9)
Baseline assessment scores, mean (SD) ^d			
Trauma-related guilt severity (TRGI)	2.5 (0.7)	2.5 (0.6)	2.5 (0.7)
Interviewer-rated PTSD severity (CAPS-5)	38.4 (9.5)	38.2 (9.5)	38.6 (9.5)
Depressive symptom severity (PHQ-9)	14.7 (6.3)	15.1 (6.5)	14.3 (6.1)
Psychological distress (BSI-18)	53.3 (9.4)	53.1 (9.4)	53.5 (9.5)
Trait shame severity (ISS)	50.5 (21.9)	51.5 (22.3)	49.5 (21.6)
Physical health (WHOQOL-BREF)	49.1 (17.6)	49.0 (16.9)	49.3 (18.3)
Psychological health (WHOQOL-BREF)	44.1 (13.0)	43.7 (13.3)	44.5 (12.8)
Social relationships (WHOQOL-BREF)	40.3 (23.3)	41.1 (21.9)	39.6 (24.8)
Environment (WHOQOL-BREF)	57.5 (17.0)	57.5 (16.7)	57.4 (17.5)

TABLE 1 (Continued)

Characteristics	Total (<i>n</i> = 145)	TrIGR (<i>n</i> = 74)	SCT (<i>n</i> = 71)
Current PTSD diagnosis (CAPS-5)	123 (84.8)	63 (85.1)	60 (84.5)
Moral injury severity (MIES)	4.08 (1.36)	4.03 (1.31)	4.13 (1.42)
No. of sessions attended out of six, mean (<i>SD</i>)	5.3 (1.7)	5.3 (1.6)	5.3 (1.8)
No. participants who had an off-protocol session ^a	13 (8.9)	12 (16.2)	1 (1.4)

Abbreviations: BSI-18, Brief Symptom Inventory-18; CAPS-5, Clinician Administered PTSD Scale for DSM-5; CPT, Cognitive Processing Therapy; ISS, Internalized Shame Scale; MIES, Moral Injury Events Scale; PE, Prolonged Exposure; PHQ-9, Patient Health Questionnaire-9; PTSD, posttraumatic stress disorder; SCT, supportive counseling therapy; TRGI, Trauma-Related Guilt Inventory; TrIGR, trauma-informed guilt reduction therapy; WHOQOL-BREF, the abbreviated version of the World Health Organization Quality of Life measure.

^aData are expressed as No. (%) unless otherwise indicated. Numbers reflect percentages out of full sample.

^bTrauma exposure assessed by the Life Events Checklist for DSM-5 (LEC-5). Responses endorsing "witnessed it" or "happened to me" were coded as trauma exposure for that trauma type.

^cOf the 100 participants who reported taking a psychotropic medication, 43% were on antidepressants, 16% on sleep medication, 15% on mood stabilizers, 8% on anti-anxiety medication, 7% on antipsychotics; 11% reported that they were on a psychotropic but did not report which medication.

^dFor descriptions of score ranges, see Section 2 of the text.

^eSince participants in SCT decided what would be discussed in session, off protocol sessions were generally not needed to address emergent issues.

Norman et al., 2019), which postulates that guilt can be adaptive when it helps shape one's actions to be more prosocial and values-driven, but becomes nonadaptive when distress is taken as evidence of wrongdoing and leads to avoidance of thinking about the traumatic event. Shame develops when trauma survivors negatively judge not just their actions ("I did something bad") but their entire selves ("I am bad") for their role in the trauma (Haller et al., 2020; Norman et al., 2014; Pugh et al., 2015). This cycle results in common cognitive errors that serve to maintain guilt, shame, and distress indefinitely and is thought to contribute to greater severity of psychopathology.

Sessions 1 and 2 included an overview of the NAGS model and discussion of common sources of trauma-related guilt. Sessions 3 and 4 utilized cognitive restructuring to help participants evaluate four types of cognitions (e.g., hindsight bias) that have been identified in prior research as contributing to posttraumatic guilt (Kubany et al., 1995). Therapists helped participants identify the function guilt has served in expressing important values (e.g., It is how I honor the memory of someone who died, If I didn't feel bad then I would really be a monster). Sessions 5 and 6 focused on identifying adaptive ways to express values other than through guilt, as well as setting realistic goals consistent with important values. TrIGR does not try to convince patients their guilt is inaccurate or that the trauma was not their fault. Rather, the goal is to help people put their actions during a traumatic event into context and help them move toward expressing values in a more positive way marked by less impairment and suffering.

SCT (Walters et al., 2020) is a present-centered, nondirective therapy based on Present Centered Therapy (PCT; Belsher et al., 2019) that excludes the problem solving component and daily diary included in PCT. SCT emphasizes principles of unconditional positive regard, genuineness, and empathic understanding. The first session includes psychoeducation about trauma-related guilt and common reactions. Subsequently, participants are free to choose the

content of each session. Participants can discuss guilt and trauma if they choose and therapists respond to this content as they would any other content area—with an open, nonjudgmental stance and unconditional positive regard. We selected SCT as the comparison intervention, because as is recommended for early stage II efficacy trials (Edmond et al., 2018; Guidi et al., 2018; Onken et al., 2014; Schnurr et al., 2005), it would provide a credible therapeutic comparison to control for the nonspecific aspects that characterize most therapy. SCT has been used as a control condition in previous psychosocial interventions trials, including with veterans (e.g., Walters et al., 2020).

Study therapists were 21 licensed psychologists, postdoctoral fellows, and doctoral students who were trained in therapy protocols through didactics, videos, and practice sessions. They received weekly supervision. Ten percent of sessions were randomly selected for fidelity rating. Scores ≥ 5 indicated strong adherence (1 = 0% of the time, 7 = >90% of the time) and competence (1 = very poor, 7 = excellent). TrIGR (adherence: $M = 6.41$, $SD = 1.00$; competence: $M = 5.85$, $SD = 1.13$) and SCT (adherence: $M = 6.61$, $SD = 0.97$; competence: $M = 5.83$, $SD = 1.19$) both showed strong fidelity ratings.

2.6 | Statistical analysis plan

Power analysis based on guilt determined 59 participants per group would provide 80% power to detect a medium standardized effect size with a two-tailed test and alpha at .05. A target total sample of 142 allowed for 17% study attrition.

To test the prespecified primary outcome of change in trauma-related guilt severity, an initial linear mixed model assessed TRGI change between baseline and 6-month follow-up (i.e., baseline to 8 months later) between treatment conditions. Subsequent LMMs analyzed guilt, PTSD, depression, trait shame, QoL total scores and

psychological distress T-scores at baseline, posttreatment, 3- and 6-month follow-up, using SPSS version 26. These models allowed for an intent-to-treat approach where all available data from randomized participants were included to estimate unbiased parameter estimates under the missing at random assumption. Treatment condition, time, and their interaction were treated as fixed effects, and the intercept was specified as a random effect to account for the repeated observations within participants. Analyses were conducted using an identity covariance matrix for the random effects and an autoregressive covariance matrix for the repeated effect of time. Between-group effect sizes (Cohen's d) were calculated for the 6-month follow-up visit using the model-based estimated marginal means from the 6-month follow-up visit and variance of all randomized participants at baseline.

Using available data at 6-month follow-up, we compared treatment conditions on PTSD *treatment response* (defined as ≥ 10 -point improvement in severity on the CAPS-5) (Schnurr et al., 2015). For the subset of patients meeting diagnostic criteria for PTSD at baseline ($n = 124$), we compared *loss of diagnosis* (defined as PTSD treatment response, plus no longer meeting DSM-5 symptom criteria and severity < 25 on the CAPS-5; Schnurr et al., 2015) and *remission*

(defined as loss of diagnosis plus severity < 12 on the CAPS-5; Norman et al., 2019). For those with mild or higher depression scores (> 5 on the PHQ-9; Löwe et al., 2004; McMillan et al., 2010) at baseline ($n = 138$), we compared *clinically meaningful change in depression* (defined as a ≥ 5 -point reduction on the PHQ-9; Löwe et al., 2004; McMillan et al., 2010).

3 | RESULTS

Figure 1 shows the Consort Diagram; 184 Veterans were enrolled with 145 ultimately randomized. TrIGR and SCT did not statistically differ on background variables or baseline measures of the primary outcomes (Table 1). Mean number of sessions attended [TrIGR $M = 5.3$, $SD = 1.6$; SCT $M = 5.3$, $SD = 1.8$], $t(143) = 0.15$, $p = .88$ and rates of treatment completion, a priori designated as attendance of 4+ on protocol sessions, [TrIGR $n = 63$; 85.1%; SCT $n = 61$; 85.9%], $\chi^2(1, N = 145) = 0.02$, $p = .90$, did not differ between conditions.

TrIGR showed greater change in guilt than SCT between baseline and 6-month follow-up (treatment $\times$ time interaction = -0.63 , 95% confidence interval [CI]: -0.89 , -0.37 , $F(1, 117.9) = 22.4$, $p < .001$;




FIGURE 1 Consort Flow Diagram. SCT, supportive care therapy; TrIGR, trauma-informed guilt reduction therapy

$d = 0.99$). The estimated marginal means (and 95% CIs) from the mixed models for outcomes overall time points are shown in Table 2. Guilt scores decreased in both conditions, with a significantly greater decrease for TrIGR (treatment $\times$ time, -0.22 ; $F(1, 455.2) = 18.49$, $p = .001$; $d = 0.92$) (Figure 2). PTSD symptom severity showed the same pattern of results (treatment $\times$ time, -2.26 ; $F(1, 468.3) = 6.76$, $p = .010$; $d = 0.81$), as did depression (treatment $\times$ time, -1.28 ; $F(1, 454.6) = 7.51$, $p = .006$; $d = 0.43$) (Figure 2). Psychological distress and trait shame decreased significantly, but these changes were not statistically different between conditions. There were no significant treatment, time, or treatment $\times$ time interaction effects for any of the QoL domains (physical health, psychological health, social relationships, or environment).

Between baseline and 6-month follow-up, TrIGR had significantly higher likelihood than SCT of PTSD treatment response (67% vs. 40%), loss of PTSD diagnosis (50% vs. 14%), and clinically meaningful change in depression (54% vs. 27%). Treatment conditions did not differ statistically on rates of PTSD remission (Figure 3).

4 | DISCUSSION

We evaluated whether TrIGR, a relatively brief intervention targeting trauma-related guilt, would reduce guilt, PTSD and depression symptoms, general psychological distress, trait shame, and QoL in a sample of military veterans. Consistent with our hypotheses, veterans who received TrIGR showed greater reduction in guilt and PTSD symptoms (with a large between-group effect size) and depression (with a moderate effect size) than veterans who received supportive therapy. As seen in Figure 3, we saw greater reductions in guilt for TrIGR compared to SCT by the end of treatment, while differences in PTSD and depression symptoms between treatments grew larger over the follow-up time points. This pattern is consistent with the NAGS model which presupposes that as guilt reduces so does avoidance and that as people engage in more valued activities, decreased avoidance and increased behavioral activation may also contribute to symptom reduction (Norman et al., 2014).

While a PTSD diagnosis was not a requirement, most of the sample (84.8%) met criteria for PTSD. Half of participants in TrIGR with PTSD lost their PTSD diagnosis and more than two-thirds showed clinically meaningful response. Among those who endorsed moderate or higher depressive symptoms at baseline, more than half had clinically meaningful change. These findings are notable given that TrIGR focuses primarily on trauma-related guilt, not PTSD or depression broadly. We considered whether these findings may be because more people who received TrIGR went on to other evidence-based PTSD treatment available at the study sites during the trial (specifically, these were PE or CPT) in the follow-up period, but did not find significant differences (four people in TrIGR and five people in SCT went on to PE or CPT during follow-up). Results suggest that for many with PTSD who report trauma-related guilt, addressing the guilt can lead to meaningful improvements in PTSD and depression as well.

TABLE 2 Prespecified study outcomes at all assessment time points

Outcome and time point	Marginal mean from linear mixed models (95% CI)	
	TrIGR	SCT
Guilt severity (TRGI) ^a		
Baseline	2.5 (2.3–2.7)	2.5 (2.3–2.7)
After treatment	1.7 (1.5–1.9)	2.3 (2.1–2.5)
3-month follow-up	1.6 (1.4–1.8)	2.2 (2.1–2.4)
6-month follow-up	1.6 (1.4–1.8)	2.2 (1.9–2.4)
PTSD severity (CAPS-5) ^b		
Baseline	38.2 (35.5–40.9)	38.6 (35.9–41.4)
After treatment	29.4 (26.6–32.2)	32.6 (29.7–35.6)
3-month follow-up	27.6 (24.6–30.5)	31.7 (28.7–34.8)
6-month follow-up	23.3 (20.2–26.4)	30.9 (27.9–34.0)
Depressive symptom severity (PHQ-9) ^c		
Baseline	15.1 (13.6–16.6)	14.4 (12.9–15.9)
After treatment	11.4 (9.8–12.9)	13.6 (12.0–15.2)
3-month follow-up	10.9 (9.3–12.5)	13.0 (11.3–14.7)
6-month follow-up	9.8 (8.0–11.5)	12.5 (10.8–14.2)
Psychological distress (BSI-18) ^d		
Baseline	53.1 (50.9–55.3)	54.0 (51.7–56.3)
After treatment	48.5 (46.2–50.8)	50.3 (47.9–52.7)
3-month follow-up	47.8 (45.4–50.1)	52.3 (49.9–54.8)
6-month follow-up	47.3 (44.8–49.9)	49.0 (46.5–51.6)
Trait shame severity (ISS) ^e		
Baseline	51.4 (46.3–56.6)	49.6 (44.3–54.8)
After treatment	39.2 (33.9–44.4)	43.7 (38.2–49.1)
3-month follow-up	37.9 (32.4–43.3)	43.9 (38.3–49.6)
6-month follow-up	37.4 (31.6–43.1)	41.9 (36.1–47.7)
Physical health (WHOQOL-BREF) ^f		
Baseline	49.0 (44.8–53.3)	49.2 (44.9–53.6)
After treatment	54.2 (49.8–58.6)	51.8 (47.2–56.3)
3-month follow-up	53.9 (49.4–58.5)	48.1 (43.3–52.8)
6-month follow-up	53.9 (49.1–58.8)	49.4 (44.5–54.2)
Psychological health (WHOQOL-BREF) ^g		
Baseline	43.7 (40.5–46.9)	44.5 (41.3–47.8)
After treatment	47.2 (43.9–50.6)	47.4 (43.9–50.8)
3-month follow-up	46.8 (43.4–50.2)	46.6 (42.9–50.2)
6-month follow-up	48.3 (44.6–51.9)	44.4 (40.7–48.0)
Social relationships (WHOQOL-BREF) ^h		
Baseline	41.1 (35.7–46.5)	39.6 (34.0–45.1)
After treatment	44.5 (38.8–50.1)	41.1 (35.3–46.8)

(Continues)

TABLE 2 (Continued)

Outcome and time point	Marginal mean from linear mixed models (95% CI)	
	TrIGR	SCT
3-month follow-up	47.5 (41.7–53.2)	38.9 (32.9–45.1)
6-month follow-up	45.9 (39.9–52.1)	37.9 (31.9–44.1)
Environment (WHOQOL-BREF) ⁱ		
Baseline	57.5 (53.6–61.5)	57.4 (53.3–61.4)
After treatment	61.5 (57.3–65.6)	56.7 (52.4–60.9)
3-month follow-up	61.6 (57.4–65.9)	57.9 (53.3–62.4)
6-month follow-up	62.2 (57.6–66.7)	55.5 (50.9–59.9)

Note: Time is coded 0 = Baseline, 1 = After treatment, 2 = 3-month follow-up, 3 = 6-month follow-up.

Abbreviations: BSI-18, Brief Symptom Inventory-18; CAPS-5, Clinician Administered PTSD Scale for DSM-5; CI, confidence interval; CPT, Cognitive Processing Therapy; ISS, Internalized Shame Scale; MIES, Moral Injury Events Scale; PE, Prolonged Exposure; PHQ-9, Patient Health Questionnaire-9; PTSD, posttraumatic stress disorder; SCT, supportive counseling therapy; TRGI, Trauma-Related Guilt Inventory; TrIGR, trauma-informed guilt reduction therapy; WHOQOL-BREF, the abbreviated version of the World Health Organization Quality of Life measure.

^aSlope = −0.12 (95% CI: −0.19 to −0.05); group × time interaction = −0.22 (95% CI: −0.32 to −0.12).

^bSlope = −2.75 (95% CI: −3.96 to −1.53); group × time interaction = −2.26 (95% CI: −3.97 to −0.55).

^cSlope = −0.65 (95% CI: −1.30 to 0.01); group × time interaction = −1.28 (95% CI: −2.21 to −0.36).

^dSlope = −1.59 (95% CI: −2.56 to −0.62); group × time interaction = −0.63 (95% CI: −1.98 to 0.72).

^eSlope = −2.88 (95% CI: −4.99 to −0.78); group × time interaction = −2.54 (95% CI: −5.49 to 0.40).

^fSlope = 0.27 (95% CI: −1.48 to 2.01); group × time interaction = 1.78 (95% CI: −0.68 to 4.23).

^gSlope = 0.20 (95% CI: −1.19 to 1.59); group × time interaction = 1.50 (95% CI: −0.45 to 3.46).

^hSlope = −0.46 (95% CI: −2.70 to 1.78); group × time interaction = 2.75 (95% CI: −0.40 to 5.91).

ⁱSlope = −0.26 (95% CI: −2.05 to 1.53); group × time interaction = 2.32 (95% CI: −0.20 to 4.85).

Reductions in overall psychological distress and trait shame did not differ by treatment condition. It is possible that both interventions are comparable at reducing these or that more time is needed to see downstream differences in the interventions. In the case of the BSI-18, baseline T-scores in our sample were in the normal range ($M = 53.3$, psychological distress is considered ≥ 63 ; Derogatis, 2001), which suggests that the BSI did not capture the type of distress participants were experiencing. PTSD and other trauma-related disorders were removed from anxiety disorders between DSM-IV and DSM-5 because of recognition that there were phenotypes of posttraumatic distress not characterized by prominent anxiety. Our findings of a distressed sample with high guilt but normal range BSI-18 scores lend support to this notion.

At the time we planned this study, a measure of trauma-related shame was not yet available (there is one now, Øktedalen et al., 2014, which we added mid-way through the study). Thus, we selected a well-validated scale of trait shame to examine shame in some form (Cook, 1987; Rybak & Brown, 1996). Trait shame, however, is likely not caused by trauma and likely not sensitive to trauma-focused intervention. In fact, trait shame may be a moderator of trauma-related shame, possibly contributing to severity or impacting treatment response.

QoL did not change significantly in the trial. How to interpret this is challenging because there has been limited use of the WHO-QOL-BREF in PTSD treatment research (Fortin et al., 2021). It is possible neither intervention improved QoL, more time is needed to see improvement in QoL, or that the WHO-QOL-BREF did not capture change that occurred.

Attendance in both conditions was high (over 5 of 6 sessions), which is notable in a sample of post-9/11 veterans, a demographic group known to be challenging to retain in psychotherapy (Erbes et al., 2009; Goetter et al., 2015; Mott et al., 2014). The focus on guilt may have contributed to high attendance if it was seen by participants as highly relevant to their experiences. Another possibility is that the brevity of the intervention contributed to low dropout. Written Exposure Therapy, a PTSD intervention of similar length, has similarly high attendance rates (Sloan et al., 2018). If patients find it easier to complete a shorter intervention, length may be an important factor for investigators to consider when developing new interventions.

Over the past decade the concept of moral injury has garnered a great deal of interest and attention. Guilt is considered a prominent feature of moral injury (Griffin et al., 2019; Litz et al., 2009; Williamson et al., 2021). The high mean MIES scores show that the study drew a sample high in exposure to moral injury. Unfortunately, validated measures of change in moral injury are not yet available, thus we were not able to examine in this study if TrIGR is effective in reducing moral injury. Such measures are under development so that future studies will be able to examine if TrIGR is effective in reducing moral injury.

Limitations include a homogenous sample of predominantly male, non-Hispanic, majority white (63%) veterans with deployment traumas, which may limit generalizability of the findings to more diverse and nonveteran populations and other trauma types. In addition to reducing trauma-related guilt, TrIGR is intended to reduce trauma-related shame and distress from moral injury (Haller et al., 2020; Norman et al., 2014; Norman et al., 2019). Unfortunately, validated assessments sensitive to measuring change in these constructs were not available when we planned the study and, as a result, we did not assess TrIGR's efficacy in regard to these. Many participants (48.3%) reported previous receiving PE or CPT. However, we did not collect information about how long ago participants received these therapies, whether they completed them, or if they received any other evidence-based psychotherapies for PTSD. While reengaging in valued activities is proposed to be an important component of TrIGR, whether participants reengaged in




FIGURE 2 (See caption on next page)




FIGURE 3 Percentage of treatment response, loss of diagnosis, and remission in PTSD and clinically meaningful change in depression by treatment condition at the 6-month follow-up visit. Between baseline and 6-month follow-up, TrIGR had significantly higher likelihood relative to SCT of *PTSD treatment response* (odds ratio [OR] [95% confidence interval {CI}] = 3.00 [1.32–6.84], $p = .015$), *loss of PTSD diagnosis* (OR [95% CI] = 6.21 [2.23–17.29], $p = .001$), and *clinically meaningful change in depression* (OR [95% CI] = 3.05 [1.27–7.34], $p = .023$). Treatments did not differ on rates of *PTSD remission* (OR [95% CI] = 3.03 [0.88–10.42], $p = .259$). PTSD, posttraumatic stress disorder; SCT, supportive counseling therapy; TrIGR, trauma-informed guilt reduction therapy

values was not assessed. Measuring reengagement in values and related behavior change is important for future studies.

5 | CONCLUSION

Trauma-related guilt is common, associated with greater severity of mental health symptoms, impairment, and distress, and can be challenging to treat. Veterans in particular have documented vulnerability to experiencing guilt and related problems. Our results suggest TrIGR can add value to existing treatments options because it targets a highly prevalent source of distress that may persist even after successful PTSD treatment, can be used to treat posttraumatic mental health problems even when a PTSD diagnosis is not present, and has high attendance and completion rates. Additional research is needed to understand for whom TrIGR is most effective and when in regard to other treatment options. Future studies that include nonveterans and guilt from any trauma types will help to understand the broader efficacy of TrIGR. A broad implication of this study is that targeting a prominent symptom presentation, such as one characterized by guilt, can be an effective method to reduce posttraumatic symptoms and distress. This study further raises questions about when it may be most effective to target a prominent symptom presentation such as

guilt versus targeting a diagnosis such as PTSD. Comparing TrIGR to an effective PTSD treatment for those with a prominent guilt presentation would help to answer this question.

ACKNOWLEDGEMENTS

This work was supported by the U. S. Department of Defense through the US Army Medical Research and Materiel Command (Trauma Informed Guilt Reduction Therapy; awards W81XWH-15-1-0330 and W81XWH-15-1-0331; principal investigators Dr. Norman and Dr. Capone). This material is the result of work supported with resources and the use of facilities at the Veterans Affairs San Diego Healthcare System and the Providence Veterans Affairs Medical Center. Drs. Norman, Allard, Browne, Capone, and Davis receive royalties from Elsevier Press from a book entitled "Trauma-Informed Guilt Reduction Therapy: Treating Guilt and Shame Resulting from Trauma and Moral Injury."

DATA AVAILABILITY STATEMENT

Data is not available.

PEER REVIEW

The peer review history for this article is available at <https://publons.com/publon/10.1002/da.23244>

FIGURE 2 Guilt, posttraumatic stress disorder, and depression symptom severity estimated marginal means by treatment condition at each time point. Error bars indicate 95% CIs. CAPS-5, Clinician Administered PTSD Scale for DSM-5; CI, confidence interval; PHQ-9, Patient Health Questionnaire; PTSD, posttraumatic stress disorder; SCT, supportive counseling therapy; TRGI, Trauma-Related Guilt Inventory; TrIGR, trauma-informed guilt reduction therapy

REFERENCES

- Allard, C. B., Norman, S. B., Straus, E., Kim, H. M., Stein, M. B., Simon, N. M., & Rauch, S. A. M. (2021). Reductions in guilt cognition s following prolonged exposure and/or sertraline predict subsequent improvements in PTSD and depression. *Journal of Behavior Therapy and Experimental Psychiatry*, 73, 101666. <https://doi.org/10.1016/j.jbtep.2021.101666>
- Allard, C. B., Norman, S. B., Thorp, S. R., Browne, K. C., & Stein, M. B. (2018). Mid-treatment reduction in trauma-related guilt predicts PTSD and functioning following cognitive trauma therapy for survivors of intimate partner violence. *Journal of Interpersonal Violence*, 33(23), 3610–3629. <https://doi.org/10.1177/0886260516636068>
- American Psychiatric Association. (2013). *Diagnostic and Statistical Manual of Mental Disorders* (Fifth Edition). American Psychiatric Association. <https://doi.org/10.1176/appi.books.9780890425596>
- Bannister, J. A., Colvonen, P. J., Angkaw, A. C., & Norman, S. B. (2019). Differential relationships of guilt and shame on posttraumatic stress disorder among veterans. *Psychological Trauma: Theory, Research, Practice, and Policy*, 11(1), 35–42. <https://doi.org/10.1037/tra0000392>
- Belsher, B. E., Beech, E., Evatt, D., Smolenski, D. J., Shea, M. T., Otto, J. L., Rosen, C. S., & Schnurr, P. P. (2019). Present-centered therapy (PCT) for post-traumatic stress disorder (PTSD) in adults. *The Cochrane Database of Systematic Reviews*, 2019(11), 1–85. <https://doi.org/10.1002/14651858.CD012898.pub2>
- Browne, K. C., Trim, R. S., Myers, U. S., & Norman, S. B. (2015). Trauma-related guilt: Conceptual development and relationship with posttraumatic stress and depressive symptoms. *Journal of Traumatic Stress*, 28(2), 134–141. <https://doi.org/10.1002/jts.21999>
- Bryan, C. J., Morrow, C. E., Etienne, N., & Ray-Sannerud, B. (2013). Guilt, shame, and suicidal ideation in a military outpatient clinical sample. *Depression and Anxiety*, 30(1), 55–60. <https://doi.org/10.1002/da.22002>
- Bryant, R. A., O'Donnell, M. L., Creamer, M., McFarlane, A. C., Clark, C. R., & Silove, D. (2010). The psychiatric sequelae of traumatic injury. *American Journal of Psychiatry*, 167(3), 312–320. <https://doi.org/10.1176/appi.ajp.2009.09050617>
- Capone, C., Norman, S. B., Haller, M., Davis, B., Shea, T., Browne, K., Lang, A., Schnurr, P., Golshan, S., Afari, N., Pittman, J., Allard, C., & Westendorf, L. (2021). Trauma Informed Guilt Reduction (TrIGR) therapy for guilt, shame, and moral injury resulting from trauma: Rationale, design, and methodology of a two-site randomized controlled trial. *Contemporary Clinical Trials*, 101, 106251. <https://doi.org/10.1016/j.cct.2020.106251>
- Capone, C., Tripp, J. C., Trim, R. S., Davis, B. C., Haller, M., & Norman, S. B. (2020). Comparing exposure- and coping skills-based treatments on trauma-related guilt in veterans with co-occurring alcohol use and posttraumatic stress disorders. *Journal of Traumatic Stress*, 33(4), 603–609. <https://doi.org/10.1002/jts.22538>
- Cook, D. R. (1987). Measuring shame: The Internalized Shame Scale. *Alcoholism treatment quarterly*, 4(2), 197–215. https://doi.org/10.1300/J020v04n02_12
- Derogatis, L. (2001). Brief Symptom Inventory 18. Administration, Scoring, and Procedures Manual. NCS Pearson.
- Edmond, S. N., Turk, D. C., Williams, D. A., & Kerns, R. D. (2018). Considerations of trial design and conduct in behavioral interventions for the management of chronic pain in adults. *Pain Reports*, 4(3), e655. <https://doi.org/10.1097/PR9.0000000000000655>
- Erbes, C. R., Curry, K. T., & Leskela, J. (2009). Treatment presentation and adherence of Iraq/Afghanistan era veterans in outpatient care for posttraumatic stress disorder. *Psychological services*, 6(3), 175–183. <https://doi.org/10.1037/a0016662>
- First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. (2002). *Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition*. Biometrics Research, New York State Psychiatric Institute.
- Fortin, M., Fortin, C., Savard-Kelly, P., Guay, S., & El-Baalbaki, G. (2021). The effects of psychotherapies for posttraumatic stress disorder on quality of life in the civilian population: A meta-analysis of RCTs. *Psychological Trauma: Theory, Research, Practice and Policy*, 673–683. <https://doi.org/10.1037/tra0000992>
- Friedman, M. J., Resick, P. A., Bryant, R. A., & Brewin, C. R. (2011a). Considering PTSD for DSM-5. *Depression and Anxiety*, 28(9), 750–769. <https://doi.org/10.1002/da.20767>
- Friedman, M. J., Resick, P. A., Bryant, R. A., Strain, J., Horowitz, M., & Spiegel, D. (2011b). Classification of trauma and stressor-related disorders in DSM-5. *Depression and Anxiety*, 28(9), 737–749. <https://doi.org/10.1002/da.20845>
- Goetter, E. M., Bui, E., Ojserkis, R. A., Zakarian, R. J., Brendel, R. W., & Simon, N. M. (2015). A systematic review of dropout from psychotherapy for posttraumatic stress disorder among Iraq and Afghanistan combat veterans. *Journal of Traumatic Stress*, 28(5), 401–409. <https://doi.org/10.1002/jts.22038>
- Griffin, B. J., Purcell, N., Burkman, K., Litz, B. T., Bryan, C. J., Schmitz, M., Villierme, C., Walsh, J., & Maguen, S. (2019). Moral injury: An integrative review. *Journal of Traumatic Stress*, 32(3), 350–362. <https://doi.org/10.1002/jts.22362>
- Guidi, J., Brakemeier, E.-L., Bockting, C. L. H., Cosci, F., Cuijpers, P., Jarrett, R. B., Linden, M., Marks, I., Peretti, C. S., Rafanelli, C., Rief, W., Schneider, S., Schnyder, U., Sensky, T., Tomba, E., Vazquez, C., Vieta, E., Zipfel, S., Wright, J. H., & Fava, G. A. (2018). Methodological recommendations for trials of psychological interventions. *Psychotherapy and Psychosomatics*, 87(5), 276–284. <https://doi.org/10.1159/000490574>
- Haller, M., Norman, S. B., Davis, B. C., Capone, C., Browne, K., & Allard, C. B. (2020). A model for treating COVID-19-related guilt, shame, and moral injury. *Psychological Trauma: Theory, Research, Practice, and Policy*. <https://doi.org/10.1037/tra0000742>
- Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: Validity of a brief depression severity measure. *Journal of General Internal Medicine*, 16(9), 606–613. <https://doi.org/10.1046/j.1525-1497.2001.016009606.x>
- Kubany, E. S., Abueg, F. R., Kilauano, W. L., Manke, F. P., & Kaplan, A. S. (1997). Development and validation of the sources f trauma-related guilt survey—War-zone version. *Journal of Traumatic Stress*, 10(2), 235–258. <https://doi.org/10.1023/A:1024878112553>
- Kubany, E. S., Abueg, F. R., Owens, J. A., Brennan, J. M., Kaplan, A. S., & Watson, S. B. (1995). Initial examination of a multidimensional model of trauma-related guilt: Applications to combat veterans and battered women. *Journal of Psychopathology and Behavioral Assessment*, 17(4), 353–376. <https://doi.org/10.1007/BF02229056>
- Kubany, E. S., Haynes, S. N., Abueg, F. R., Manke, F. P., Brennan, J. M., & Stahura, C. (1996). Development and validation of the Trauma-Related Guilt Inventory (TRGI). *Psychological Assessment*, 8(4), 428–444. <https://doi.org/10.1037/1040-3590.8.4.428>
- Larsen, S. E., Fleming, C. J. E., & Resick, P. A. (2019). Residual symptoms following empirically supported treatment for PTSD. *Psychological Trauma: Theory, Research, Practice and Policy*, 11(2), 207–215. <https://doi.org/10.1037/tra0000384>
- Litz, B. T., Stein, N., Delaney, E., Lebowitz, L., Nash, W. P., Silva, C., & Maguen, S. (2009). Moral injury and moral repair in war veterans: A preliminary model and intervention strategy. *Clinical Psychology Review*, 29(8), 695–706. <https://doi.org/10.1016/j.cpr.2009.07.003>
- Löwe, B., Unützer, J., Callahan, C. M., Perkins, A. J., & Kroenke, K. (2004). Monitoring depression treatment outcomes with the patient health questionnaire-9. *Medical Care*, 42(12), 1194–1201.
- Marx, B. P., Foley, K. M., Feinstein, B. A., Wolf, E. J., Kaloupek, D. G., & Keane, T. M. (2010). Combat-related guilt mediates the relations between exposure to combat-related abusive violence and psychiatric diagnoses. *Depression and Anxiety*, 27(3), 287–293. <https://doi.org/10.1002/da.20659>
- McMillan, D., Gilbody, S., & Richards, D. (2010). Defining successful treatment outcome in depression using the PHQ-9: A comparison of

- methods. *Journal of Affective Disorders*, 127(1–3), 122–129. <https://doi.org/10.1016/j.jad.2010.04.030>
- Miller, M. W., Wolf, E. J., Kilpatrick, D. G., Resnick, H. S., Marx, B. P., Holowka, D. W., Keane, T. M., Rosen, R. C., & Friedman, M. J. (2013). The prevalence and latent structure of proposed DSM-5 posttraumatic stress disorder symptoms in U.S. national and veteran samples. *Psychological Trauma: Theory, Research, Practice, and Policy*, 5, 501–512. <https://doi.org/10.1037/a0029730>
- Mott, J. M., Mondragon, S., Hundt, N. E., Beason-Smith, M., Grady, R. H., & Teng, E. J. (2014). Characteristics of U.S. veterans who begin and complete prolonged exposure and cognitive processing therapy for PTSD. *Journal of Traumatic Stress*, 27(3), 265–273. <https://doi.org/10.1002/jts.21927>
- Myers, U. S., Wilkins, K. C., Allard, C. B., & Norman, S. B. (2012). Trauma-related guilt inventory: Review of psychometrics and directions for future research. *Advances in Psychology Research*, 91, 71–91.
- Nash, W. P., Marino Carper, T. L., Mills, M. A., Au, T., Goldsmith, A., & Litz, B. T. (2013). Psychometric evaluation of the Moral Injury Events Scale. *Military Medicine*, 178(6), 646–652. <https://doi.org/10.7205/MILMED-D-13-00017>
- Nishith, P., Nixon, R. D. V., & Resick, P. A. (2005). Resolution of trauma-related guilt following treatment of PTSD in female rape victims: A result of cognitive processing therapy targeting comorbid depression? *Journal of Affective Disorders*, 86(2–3), 259–265. <https://doi.org/10.1016/j.jad.2005.02.013>
- Norman, S. B., Allard, C., Browne, K., Capone, C., Davis, B., & Kubany, E. (2019). *Trauma informed guilt reduction therapy: Treating guilt and shame resulting from trauma and moral injury*. Elsevier Academic Press
- Norman, S. B., Haller, M., Kim, H. M., Allard, C. B., Porter, K. E., Stein, M. B., Venners, M. R., Authier, C. C., & Rauch, S. A. M., Progress Team. (2018). Trauma related guilt cognitions partially mediate the relationship between PTSD symptom severity and functioning among returning combat veterans. *Journal of Psychiatric Research*, 100, 56–62. <https://doi.org/10.1016/j.jpsychires.2018.02.003>
- Norman, S. B., Trim, R., Haller, M., Davis, B. C., Myers, U. S., Colvonen, P. J., Blanes, E., Lyons, R., Siegel, E. Y., Angkaw, A. C., Norman, G. J., & Mayes, T. (2019). Efficacy of integrated exposure therapy vs integrated coping skills therapy for comorbid posttraumatic stress disorder and alcohol use disorder: A randomized clinical trial. *JAMA Psychiatry*, 76(8), 791–799. <https://doi.org/10.1001/jamapsychiatry.2019.0638>
- Norman, S. B., Wilkins, K. C., Myers, U. S., & Allard, C. B. (2014). Trauma informed guilt reduction therapy with combat veterans. *Cognitive and behavioral practice*, 21(1), 78–88.
- Økstedalen, T., Hagtvet, K. A., Hoffart, A., Langkaas, T. F., & Smucker, M. (2014). The Trauma related shame inventory: Measuring trauma-related shame among patients with PTSD. *Journal of psychopathology and behavioral assessment*, 36(4), 600–615. <https://doi.org/10.1007/s10862-014-9422-5>
- Onken, L. S., Carroll, K. M., Shoham, V., Cuthbert, B. N., & Riddle, M. (2014). Reenvisioning clinical science: Unifying the discipline to improve the public health. *Clinical Psychological Science: A Journal of the Association for Psychological Science*, 2(1), 22–34. <https://doi.org/10.1177/2167702613497932>
- Owens, G. P., Chard, K. M., & Cox, T. A. (2008). The relationship between maladaptive cognitions, anger expression, and posttraumatic stress disorder among veterans in residential treatment. *Journal of Aggression, Maltreatment & Trauma*, 17(4), 439–452. <https://doi.org/10.1080/10926770802473908>
- Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., & Mann, J. J. (2011). The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. *The American Journal of Psychiatry*, 168(12), 1266–1277. <https://doi.org/10.1176/appi.ajp.2011.10111704>
- Pugh, L. R., Taylor, P. J., & Berry, K. (2015). The role of guilt in the development of post-traumatic stress disorder: A systematic review. *Journal of Affective Disorders*, 182, 138–150. <https://doi.org/10.1016/j.jad.2015.04.026>
- Rosellini, A. J., Szentkúti, P., Horváth-Puhó, E., Smith, M. L., Galatzer-Levy, I., Lash, T. L., Galea, S., Schnurr, P. P., Sørensen, H. T., & Gradus, J. L. (2021). Latent classes of posttraumatic psychiatric comorbidity in the general population. *Journal of Psychiatric Research*, 136, 334–342. <https://doi.org/10.1016/j.jpsychires.2021.02.013>
- Rybak, C. J., & Brown, B. M. (1996). Assessment of internalized shame: Validity and reliability of the internalized shame scale. *Alcoholism Treatment Quarterly*, 14(1), 71–83. https://doi.org/10.1300/J020V14N01_07
- Schnurr, P. P., Chard, K. M., Ruzek, J. I., Chow, B. K., Shih, M.-C., Resick, P. A., Foa, E. B., Marx, B. P., Huang, G. D., & Lu, Y. (2015). Design of VA cooperative study #591: CERV-PTSD, comparative effectiveness research in veterans with PTSD. *Contemporary Clinical Trials*, 41, 75–84. <https://doi.org/10.1016/j.cct.2014.11.017>
- Schnurr, P. P., Friedman, M. J., Engel, C. C., Foa, E. B., Shea, M. T., Resick, P. M., James, K. E., & Chow, B. K. (2005). Issues in the design of multisite clinical trials of psychotherapy: VA Cooperative Study No. 494 as an example. *Contemporary Clinical Trials*, 26(6), 626–636. <https://doi.org/10.1016/j.cct.2005.09.001>
- Skevington, S. M., Lotfy, M., & O'Connell, K. A., WHOQOL Group. (2004). The World Health Organization's WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A report from the WHOQOL group. *Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation*, 13(2), 299–310. <https://doi.org/10.1023/B:QURE.0000018486.91360.00>
- Sloan, D. M., Marx, B. P., Lee, D. J., & Resick, P. A. (2018). A brief exposure-based treatment vs cognitive processing therapy for posttraumatic stress disorder: A randomized noninferiority clinical trial. *JAMA Psychiatry*, 75(3), 233–239. <https://doi.org/10.1001/jamapsychiatry.2017.4249>
- Steenkamp, M. M., Litz, B. T., Hoge, C. W., & Marmar, C. R. (2015). Psychotherapy for Military-related PTSD: A review of randomized clinical trials. *Journal of the American Medical Association*, 314(5), 489–500. <https://doi.org/10.1001/jama.2015.8370>
- Steenkamp, M. M., Litz, B. T., & Marmar, C. R. (2020). First-line psychotherapies for military-related PTSD. *Journal of the American Medical Association*, 323, 656. <https://doi.org/10.1001/jama.2019.20825>
- Walters, E. M., Jenkins, M. M., Nappi, C. M., Clark, J., Lies, J., Norman, S. B., & Drummond, S. P. A. (2020). The impact of prolonged exposure on sleep and enhancing treatment outcomes with evidence-based sleep interventions: A pilot study. *Psychological Trauma: Theory, Research, Practice and Policy*, 12(2), 175–185. <https://doi.org/10.1037/tra0000478>
- Weathers, F. W., Bovin, M. J., Lee, D. J., Sloan, D. M., Schnurr, P. P., Kaloupek, D. G., Keane, T. M., & Marx, B. P. (2018). The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. *Psychological Assessment*, 30(3), 383–395. <https://doi.org/10.1037/pas0000486>
- Williamson, V., Murphy, D., Stevelink, S. A. M., Allen, S., Jones, E., & Greenberg, N. (2021). Delivering treatment to morally injured UK military personnel and Veterans: The clinician experience. *Military Psychology*, 33(2), 115–123. <https://doi.org/10.1080/08995605.2021.1897495>

How to cite this article: Norman, S. B., Capone, C., Panza, K. E., Haller, M., Davis, B. C., Schnurr, P. P., Shea, M. T., Browne, K., Norman, G. J., Lang, A. J., Kline, A. C., Golshan, S., Allard, C. B., & Angkaw, A. (2022). A clinical trial comparing trauma-informed guilt reduction therapy (TrIGR), a brief intervention for trauma-related guilt, to supportive care therapy. *Depression and Anxiety*, 1–12. <https://doi.org/10.1002/da.23244>



Trauma-Informed Guilt Reduction Therapy: Overview of the Treatment and Research

Sonya Norman, PhD^{1,2,3,*} 

Address

¹Executive Division, National Center for PTSD, White River Junction, VT, USA

Email: snorman@ucsd.edu

²Department of Psychiatry, San Diego School of Medicine, University of California, San Diego, CA, USA

³VA Center of Excellence for Stress and Mental Health, 3350 La Jolla Village Drive, MC 116B, San Diego, CA 92161, USA

This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2022

This article is part of the Topical Collection on *Moral Injury*.

Keywords Moral injury · Trauma-related guilt · Trauma-related shame · PTSD · Depression · Psychotherapy

Abstract

Purpose of Review The purpose of this review is to describe Trauma-Informed Guilt Reduction Therapy (TrIGR), the Non-Adaptive Guilt and Shame (NAGS) model that underlies TrIGR, and the research supporting the use of TrIGR to treat the guilt and shame components of moral injury. TrIGR is a 6-session individual psychotherapy that helps clients consider their role in the traumatic event and find constructive ways to express important values, so that they no longer need to express values by suffering through guilt and shame.

Recent Findings A recently completed randomized controlled trial of TrIGR versus supportive care therapy included 144 post-9/11 veterans. TrIGR showed greater reductions in trauma-related guilt, PTSD symptoms, and depression symptoms. Participants in TrIGR had greater likelihood of losing their PTSD diagnosis and showing clinical meaningful change in PTSD and depression symptoms. Mean attendance was high; 5.3 out of 6 sessions.

Summary TrIGR is efficacious in reducing guilt that is common to moral injury as well as PTSD and depression symptoms among combat veterans. The next steps in the program of research to develop and evaluate TrIGR are studies with diverse trauma types and populations as well as relative effectiveness studies comparing TrIGR to other evidence-based treatments for moral injury and PTSD.

Introduction

The purpose of this review is to describe Trauma-Informed Guilt Reduction Therapy (TriGR), the Non-Adaptive Guilt and Shame (NAGS) model that

underlies TriGR, and the research supporting the use of TriGR to treat the guilt and shame components of moral injury.

Guilt and shame are hallmark features of moral injury

While there is no one consensus definition of moral injury, it is generally considered to be the long-term psychological, behavioral, social, and sometimes spiritual distress that occurs after one experiences an event that violates deeply held morals and values [1, 2]. Two hallmark symptoms of moral injury are guilt and shame [1, 2, 3]. Guilt is a hybrid of negative thoughts and emotions that arises when people blame themselves for all or part of the negative outcome of an event (e.g., “I did something bad”) [4]. Shame is when one judges not just their actions but their entire self negatively (e.g., “I am bad”) [5]. Difficulty forgiving oneself for the transgression of values is also considered common in moral injury [6].

Trauma-related guilt such as that seen in moral injury occurs frequently among trauma survivors [7]. For example, one study of VA enrolled veterans who had experienced trauma found that over 40% reported that they had experienced guilt in the past month [7]. In addition to being common, trauma-related guilt is associated with a variety of negative post-traumatic mental health outcomes. In our research with veterans, we have found that trauma-related guilt is positively associated with the severity of PTSD and depression symptoms [8, 9], with aggression [10], and with poorer overall psychosocial functioning and in the specific domains of interpersonal functioning, professional functioning, and self-care [11]. Extant work shows it is also associated with suicidal ideation, even when controlling for combat exposure or PTSD symptoms [12, 13].

For people with PTSD, trauma-related guilt is one of the symptoms likely to linger, even after successful PTSD treatment [14, 15]. Research with clinicians shows that they find moral injury, and guilt specifically, challenging to treat and an area where they would like more intervention strategies [16, 17]. Less is known about trauma-related shame because a measure to assess such shame was only recently validated and published [18]. However, studies suggest that trauma-related guilt in the absence of shame is rare and that shame may in fact explain much of the variance in the associations between guilt and negative outcomes [10, 19]. Because moral injury and the associated hallmark symptoms of guilt and shame are common, distressing, debilitating, and challenging to treat, we developed Trauma-Informed Guilt Reduction Therapy (TriGR).

Developing TrIGR

Our study team's attention was first drawn to moral injury and specifically the guilt and shame components in our clinical work with combat veterans who had served in Iraq and Afghanistan. Many were coming in for mental health treatment with primary presentation of moral injury, having to live with something they did or did not do in the context of war that went against their morals and values, with guilt and shame prominent in their clinical presentation. Many had PTSD but some did not, so not all were appropriate for PTSD treatment. Some had completed disorder specific treatment (e.g., PTSD, depression) but still had prominent and debilitating guilt. We saw in our work and in the extent literature [16, 17] that therapists were asking for more information on how to treat this kind of moral injury based, trauma-related guilt.

To develop TrIGR, we first conceived a model of how trauma-related guilt and shame affect mental health which we called the Non-Adaptive Guilt and Shame (NAGS) model (Fig. 1) [9, 20]. According to the NAGS model, some people experience guilt after a traumatic event, while some do not. Among those who do experience guilt, some use the negative feelings of guilt as an opportunity to assess what values were violated (e.g., "What did I do that makes me feel so awful? How do I avoid feeling this way again?"). In such cases, guilt may help people make choices that are more in line with their values. However, sometimes people avoid thinking about the event and guilt feelings. Or their guilt stems from an event where there was no good choice and any choice would have led to a negative outcome (e.g., certain combat situations). The negative feeling of guilt may be seen as evidence that someone did something wrong, and the sense that someone did something wrong may lead to further negative feelings, creating a cycle of feeling more guilt and more guilty. The guilt becomes shame if the person comes to believe that not only did they do something bad, but that they are bad because of what they did. This cycle of negative thoughts and affect contributes to the severity of symptoms of common posttraumatic mental health problems such as PTSD




Fig. 1 Non-adaptive guilt and shame (NAGS) model.

and depression. This cycle can also contribute to self-destructive behaviors such as substance use, suicide risk, and high-risk behaviors. It may also contribute to poor or ambivalent engagement in treatment because people may come to believe that they do not deserve to feel good or do well.

We mapped the TrIGR intervention onto the NAGS model to end the cycle of guilt and shame that contributes to the severity of mental health problems and high-risk behaviors [9, 20]. The goal is to target guilt and shame to reduce some of the psychological, behavioral, social, and sometimes spiritual distress of moral injury. The overarching objective of TrIGR is to help clients consider their role in the traumatic event more comprehensively than they have previously and to help them find constructive ways to express important values, so that they no longer need to express values through suffering and high-risk behaviors (e.g., "I did something awful so now I deserve to suffer)." To help clients appraise their role in the trauma, the therapist guides the client through evaluation of four types of cognitions identified by Kubany and colleagues [4, 21]. Hindsight bias (e.g., "I knew exactly how things would turn out that day") is challenged by helping clients remember what they really knew and had the power to do at the time. The therapist and client then examine what options the client had during at the time and how each option may have played out. Clients often come to terms during this exercise with the idea that there were no good options available at the time, and that all options would have led to some bad outcome. We then help people consider the full context of what happened and the many factors that contributed to the outcome. Finally, we help people consider whether they purposely intended the bad outcome that occurred. In the last module of TrIGR, the therapist helps the client find ways to express their values in more positive ways than by feeling guilt and shame, and helps people make plan to spend time doing activities that are meaningful to them and consistent with their values.

In terms of logistics, TriGR is a 6-session individual manualized intervention. The first two sessions of TriGR cover psychoeducation about trauma-related guilt and shame and the NAGS model. The second two sessions focus on processing the trauma and guilt and shame by debriefing the four common cognitions. The final two sessions focus on understanding what values were violated during the trauma, identifying important values, and creating a plan for how to live more in-line with important values. Clients are assigned homework after each session which includes reading psychoeducational materials about guilt, listening to a recording of the session, and keeping a log of cognitions that cause feelings of guilt and shame (e.g., "I should have known better than to..."). Clients track their activities leading into the values portion of the treatment (i.e., the final two sessions) to help identify ways to build more value-driven activities into their schedule. TriGR can be delivered in person or through video conferencing.

TriGR was designed to be easy to learn and implement by therapists familiar with cognitive behavioral therapy models. In our research studies, therapists have included clinical psychology pre- and post-doctoral trainees and licensed psychologists and social workers. Therapists new to TriGR can learn the intervention through the manual and workbook which are published together in one book [20]. The treatment manual walks therapists through delivering the

intervention session by session with clinical examples based on different kinds of traumas. The workbook includes client psychoeducational materials and assignments. The book also includes chapters on preparing clients for TrIGR, troubleshooting clinical situations that may arise, and therapist self-care.

TrIGR is one of several interventions that was developed to address one or more aspects of moral injury. Others include Adaptive Disclosure [22] which focuses on strategies that are consistent with military culture to promote self-forgiveness and reparative action. The therapy is also designed to help with anger and grief from moral injury if they are present. Impact of Killing is a cognitive behavioral intervention focused on moral injury from killing others in combat [23]. The therapy discusses physiology of killing responses, self-forgiveness, spirituality, making amends, and maintaining functional gains. Building Spiritual Strength [24] addresses the spiritual strain of moral injury and works to enhance religious meaning making. The Self-Forgiveness Workbook is a 6-h self-guided intervention designed to facilitate self-forgiveness and reduce self-condemnation among people who perpetrated interpersonal offenses [25]. TrIGR is best suited when guilt and shame are present and prominent in a client's presentation. If a client prefers to take a more spiritual focus to their guilt and shame, Building Spiritual Strength may be a better choice. If a client's moral injury presents most strongly as anger or loss, Adaptive Disclosure may be the better choice. For someone who prefers self-help, the Self-Forgiveness Workbook may be a good starting point. It is likely that for some clients there is no one right choice. For example, someone who has guilt from killing in combat may benefit from TrIGR or Impact of Killing. If these are both available, shared decision making with the therapist and client may be a good method by which to decide on a treatment direction.

TrIGR research

We set out to evaluate TrIGR using Onken's stages of behavioral treatment development [26]. In summary, stage I is development and preliminary testing of the intervention, usually focused on gathering feasibility and pilot data. Studies at this stage often use single condition pre-post designs. Stage II is efficacy testing in a research setting. Randomized controlled trials are the most common design used for stage II studies. Stage III continues efficacy work while introducing elements of "real world" effectiveness such as conducting the trial in community settings or with community-based providers but maintaining a high level of control to maintain high internal validity. Stage IV moves further into effectiveness and stage V focuses on dissemination and implementation.

First pilot and feasibility study

Our first pilot trial of TrIGR (stage I) was a pre-post study with thirteen veterans who served in Iraq or Afghanistan, had guilt from a combat trauma, and met diagnostic criteria for PTSD [9]. Ten completed the intervention.

We measured trauma-related guilt, PTSD symptoms and depression. Results showed pre to post reductions in all three outcomes. Overall trauma-related guilt distress (from 3.0, SD = .48 to 2.4, SD = .89, *Cohen's d* = 1.37) and trauma-related cognitions (from 2.1, SD = .99 to 1.3, SD = .75, *Cohen's d* = 1.53) as measured by the Trauma-Related Guilt Inventory [27] reduced significantly.

In addition to examining if pre- to post-treatment change in PTSD and depression symptoms was statistically significant, we examined if change in PTSD symptoms was clinically noticeable (computed in previous studies to be a 10-point decrease on the Clinician Administered PTSD Scale for DSM-IV [CAPS] [28]; defined as representing a meaningful improvement in the life of someone with chronic PTSD [29, 30, 31]; and if change in depression was clinically significant (computed in a previous study to be 5-point decrease on the Physician Health Questionnaire-9 [PHQ-9] [32, 33]. Specifically, a 5-point change on the PHQ-9 has been shown to correspond with a moderate effect size on multiple domains of health-related quality of life and functional status [33]. Scores on the CAPS showed clinically meaningful change of over 18 points, from $M = 81.4$ (SD = 20.3) to $M = 62.0$ (SD = 36.5). Depression symptom change was also clinically meaningful going from $M = 14.2$ (SD = 6.4) to 9.3 (SD = 8.04) on the PHQ-9. Both PTSD and depression change showed large effect sizes (*Cohen's D* = 1.98 and 1.44, respectively). Participants were highly satisfied with the intervention, with a mean of over 28 out of 30 on The Client Satisfaction Questionnaire [34], our measure of treatment satisfaction. These preliminary findings suggested to us that further study of TriGR using a rigorous randomized controlled trial design (stage II) was warranted.

First randomized controlled trial

We recently completed the first stage II, randomized controlled trial of TriGR [35]. We randomized 144 Veterans who served in the conflicts in Iraq or Afghanistan and had guilt from a trauma that occurred on a deployment. Veterans were recruited from two sites, the San Diego and Providence VAs, and were randomized to receive either TriGR or supportive care therapy [36]. In supportive care therapy, clients choose the topics that are discussed in therapy and therapists respond with positive regard and support, but do not offer skills or strategies [36]. Supportive care therapy is similar to Present Centered Therapy but without the active elements of problem solving. There is no homework in this therapy. It was selected as the control condition because it has all of the non-specific elements of good therapy without active intervention strategies. This kind of passive control is appropriate for stage II behavioral intervention studies [26]. Both therapies were delivered in six individual weekly sessions. Therapists delivered both treatments with careful fidelity monitoring for both therapies which included weekly supervision and having supervisors and fidelity raters listen to audio recordings of sessions.

Results using intent-to-treat analyses showed TriGR was more effective than supportive care therapy in reducing trauma-related guilt (treatment ×

time, -0.22 ; $F(1, 455.2) = 18.49$, $p = .001$; $d = 0.92$) and PTSD (treatment $\times$ time, -2.26 ; $F(1, 468.3) = 6.76$, $p = .010$; $d = 0.81$) and depression symptoms (treatment $\times$ time, -1.28 ; $F(1, 454.6) = 7.51$, $p = .006$; $d = 0.43$). Surprisingly, 50% of people in TrIGR lost their PTSD diagnosis between baseline and 6 months (compared to 14% in supportive care therapy; OR [95% CI] = 6.21 [2.23–17.29], $p = .001$), 67% showed clinically meaningful PTSD symptom reduction (compared to 40% in supportive care therapy; defined as a > 10 point improvement in CAPS-5 severity [37]; odds ratio [OR] [95% confidence interval {CI}] = 3.00 [1.32–6.84], $p = .015$), and 54% had clinically meaningful depression symptom reduction (compared to 27% in supportive care therapy; defined as > 5 on the PHQ-9, [38]; OR [95% CI] = 3.05 [1.27–7.34], $p = .023$). These findings suggest that for those with PTSD and/or depression who have high trauma-related guilt, a treatment that is brief but targets the guilt can be effective in treating PTSD and depression symptoms.

We also measured general distress using the Brief Symptom Inventory-18 (BSI-18) [39] and quality of life using the World Health Organization Quality of Life measure [40]. We did not find differences between TrIGR and supportive care therapy. We speculated that the BSI-18, which has heavy emphasis on anxiety and somatization, may not capture the type of distress experienced by our high-guilt sample. Regarding quality of life, it was not clear if the treatments did not improve this outcome, or if this measure, which has not been validated with PTSD samples, did not capture change that may have occurred. We look forward to using more robust measures of quality of life in future studies to try to answer this question.

One surprising result was the high session attendance across both therapies ($M = 5.3$, $SD = 1.6$, in TrIGR and also 5.3 , $SD = 1.8$, $t(143) = 0.15$, $p = .88$) in supportive care therapy, out of six sessions in both cases). Rates of treatment completion, a priori defined as attending four or more of six sessions, were also high and did not differ between treatment conditions [TrIGR $n = 63$; 85.1%; SCT $n = 61$; 85.9%], $\chi^2(1, N = 145) = 0.02$, $p = .90$]. Such high attendance is unusual in any PTSD study but in particular in a sample of Iraq and Afghanistan veterans who have shown low attendance and high attrition across PTSD treatment trials [41, 42, 43]. We speculated that this may be because TrIGR is shorter than many PTSD treatments or that the focus on guilt felt more germane to the sample we recruited, and thus they continued to attend therapy.

COVID-19 pandemic study

We have a small stage II–III trial in progress to evaluate TrIGR for guilt from COVID-19 pandemic related events. The pandemic created ethically difficult scenarios for many people where they may have felt like they could not do enough or live up to their own standards [44•]. Examples include not being able to be with a loved who was very ill or dying, exposing someone to infection, or not being able to provide for family financially because of loss of a job or income. Our goal is to see if TrIGR may help reduce guilt from these kinds of ethically difficult, potentially morally injurious

scenarios. We are in the process of randomizing 72 veterans who deployed in service of Iraq or Afghanistan who have guilt from an event that occurred during the pandemic or guilt that got worse due to the pandemic. The goal was to conduct this study quickly during the pandemic; thus, sample size was based on feasibility of recruitment in the study time frame. Participants are recruited to one of three sites — the Boston, Providence or San Diego VA, and randomized to TrIGR or supportive care therapy. This study is allowing us to stretch our understanding of the applicability of TrIGR in several important ways. This study is the first evaluation of TrIGR to treat guilt from incidents that may be morally distressing and cause guilt but are do not necessarily meet Criterion A for PTSD. In our previous research, guilt had to stem from a trauma that would meet criterion A. Examples that would not meet criterion A are guilt over parenting or relationship behavior during the pandemic, or not being able to support one's family because of loss of income. It is also our first evaluation of TrIGR for non-warzone and non-military events. Also, in our previous studies the events that caused guilt generally occurred years before study entry, whereas in the pandemic study, events often occurred just months before participants entered the study. Thus, results of the trial will help inform if TrIGR can be efficacious to reduce guilt and related symptoms from recent morally distressing events and from non-military events.

Next steps in research

Our goal for the next steps of studying TrIGR is to understand how broadly applicable the treatment may be as the data we have so far are from a specific era of veterans with guilt from a specific type of trauma. This will move us further into stage III and IV research. Specifically, next steps are to evaluate TrIGR's ability to reduce guilt and related symptoms from any type of trauma (e.g., car accidents, assaults) or morally challenging life events, to evaluate its efficacy with people who are not veterans and with veterans from any service era (thus far, our research has been with post-9/11 veterans). We also appreciate that there are several efficacious treatment options for moral injury and for PTSD and believe it is important to understand TrIGR's effectiveness relative to these other treatments. This will allow clients to make informed decisions when presented with treatment options. Thus, another goal is to conduct studies comparing TrIGR to other effective treatments for moral injury and for common co-occurring problems such as PTSD.

We often get asked if there is the ideal time for someone to receive TrIGR relative to other treatments; that is, should it be a first line treatment, should it be offered after a diagnosis specific treatment when there is residual guilt, or should multiple treatments occur concurrently. It is likely that the answer to this question varies person to person based on clinical presentation and client preference, but we also see this as an empirical question that we would like to research in future studies.

Conclusions

TrIGR is a brief intervention focused on the guilt and shame components of moral injury and/or trauma. Evidence thus far suggests it is effective in reducing trauma-related guilt as well as symptoms of PTSD and depression. Future studies will assess its effectiveness with non-veterans, veterans of all eras of service, and with a broad range of traumas and stressors that violate deeply held moral beliefs and values.

Acknowledgements

Acknowledgements go to the dedicated team that has written and revised the TrIGR protocol over the years including Carolyn Allard, PhD; Kendall Browne, PhD; Christy Capone, PhD; Brittany Davis, PhD; and Moira Haller, PhD. I wish to thank Edward Kubany, PhD whose foundational work and mentorship made TrIGR possible. Thank you to our research team and the veterans who have participated in [TriGR research](#).

Funding

The study received financial support from the Department of Defense Congressionally Directed Medical Research Program Grant # W81XWH-15-1-0330.

Declarations

Conflict of Interest

This work was supported by a grant from the Department of Defense Congressionally Directed Medical Research Program, Grant # W81XWH-15-1-0330. The author, Sonya Norman, earns royalties from Elsevier Press for a book titled "Trauma Informed Guilt Reduction Therapy: Treating Guilt and Shame Resulting from Trauma and Moral Injury."

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as:

- Of importance

1. Litz BT, Stein N, Delaney E, Lebowitz L, Nash WP, Silva C, et al. Moral injury and moral repair in war veterans: a preliminary model and intervention strategy. *Clin Psychol Rev*. 2009;29(8):695–706.
 2. Griffin BJ, Purcell N, Burkman K, Litz BT, Bryan CJ, Schmitz M, et al. Moral injury: an integrative review. *J Trauma Stress*. 2019;32(3):350–62.
 3. Frankfurt S, Frazier P. A review of research on moral injury in combat veterans. *Mil Psychol*. 2016;28(5):318–30.
 4. Kubany ES, Watson SB. Guilt: elaboration of a multi-dimensional model. *Psychol Rec*. 2003;53(1):51–90.
 5. Tangney JP, Stuewig J, Mashek DJ. Moral emotions and moral behavior. *Annu Rev Psychol*. 2006;58(1):345–72.
- Excellent review of relationship between moral injury and mental health.

6. Maguen S, Norman SB. Moral injury. PTSD Res Q [Internet]. 2022 [cited 2022 Mar 15];33(1). Available from: https://www.ptsd.va.gov/publications/rq_docs/V33N1.pdf
7. Miller MW, Wolf EJ, Kilpatrick DG, Resnick HS, Marx BP, Holowka DW, et al. The prevalence and latent structure of proposed DSM-5 posttraumatic stress disorder symptoms in U.S. national and veteran samples. Psychol Trauma [Internet]. 2013 [cited 2020 May 12]; Available from: <https://www.scienceopen.com/document?vid=8ead3b36-5fc9-4abb-a947-3c29978d8aa4>
8. Browne KC, Trim RS, Myers US, Norman SB. Trauma-related guilt: conceptual development and relationship with posttraumatic stress and depressive symptoms. J Trauma Stress. 2015;28(2):134–41.
9. Norman SB, Wilkins KC, Myers US, Allard CB. Trauma informed guilt reduction therapy with combat veterans. Cogn Behav Pract. 21(1):78–88.
10. Crocker LD, Haller M, Norman SB, Angkaw AC. Shame versus trauma-related guilt as mediators of the relationship between PTSD symptoms and aggression among returning veterans. Psychol Trauma. 2016;8(4):520–7.
11. Norman SB, Haller M, Kim HM, Allard CB, Porter KE, Stein MB, et al. Trauma related guilt cognitions partially mediate the relationship between PTSD symptom severity and functioning among returning combat veterans. J Psychiatr Res. 2018;100:56–62.
12. Bryan CJ, Morrow CE, Etienne N, Ray-Sannerud B. Guilt, shame, and suicidal ideation in a military outpatient clinical sample. Depress Anxiety. 2013;30(1):55–60.
13. Marx BP, Foley KM, Feinstein BA, Wolf EJ, Kaloupek DG, Keane TM. Combat-related guilt mediates the relations between exposure to combat-related abusive violence and psychiatric diagnoses. Depress Anxiety. 2010;27(3):287–93.
14. Larsen SE, Fleming CJE, Resick PA. Residual symptoms following empirically supported treatment for PTSD. Psychol Trauma. 2019;11(2):207–15.
15. Owens GP, Chard KM, Cox TA. The relationship between maladaptive cognitions, anger expression, and posttraumatic stress disorder among veterans in residential treatment. J Aggress Maltreat Trauma. 2008;17(4):439–52.
16. Nash WP. Combat/operational stress adaptations and injuries. In: Combat stress injury: Theory, research, and management. New York, NY, US: Routledge/Taylor & Francis Group; 2007. p. 33–63. (Routledge psychosocial stress series).
17. Becker CB, Zayfert C, Anderson E. A survey of psychologists' attitudes towards and utilization of exposure therapy for PTSD. Behav Res Ther. 2004;42(3):277–92.
18. Øktedalen T, Hagtvet KA, Hoffart A, Langkaas TE, Smucker M. The Trauma related shame inventory: measuring trauma-related shame among patients with PTSD. J Psychopathol Behav Assess. 2014;36(4):600–15.
19. Bannister JA, Colvonen PJ, Angkaw AC, Norman SB. Differential relationships of guilt and shame on posttraumatic stress disorder among veterans. Psychol Trauma. 2019;11(1):35–42.
20. Norman S, Allard C, Browne K, Capone C, Davis B, Kubany E. Trauma informed guilt reduction therapy: treating guilt and shame resulting from trauma and moral injury. San Diego, CA, US: Elsevier Academic Press; 2019. xiii, 78 p. (Trauma informed guilt reduction therapy: treating guilt and shame resulting from trauma and moral injury).
21. Kubany ES, Abueg FR, Owens JA, Brennan JM, Kaplan AS, Watson SB. Initial examination of a multidimensional model of trauma-related guilt: applications to combat veterans and battered women. J Psychopathol Behav Assess. 1995;17(4):353–76.
22. Litz BT, Rusowicz-Orazem L, Doros G, Grunthal B, Gray M, Nash W, et al. Adaptive disclosure, a combat-specific PTSD treatment, versus cognitive-processing therapy, in deployed marines and sailors: a randomized controlled non-inferiority trial. Psychiatry Res. 2021;297:113761.
23. Maguen S, Burkman K, Madden E, Dinh J, Bosch J, Keyser J, et al. Impact of killing in war: a randomized, controlled pilot trial. J Clin Psychol. 2017;73(9):997–1012.
24. Harris JI, Erbes CR, Engdahl BE, Thurais P, Murray-Swank N, Grace D, et al. The effectiveness of a trauma focused spiritually integrated intervention for veterans exposed to trauma. J Clin Psychol. 2011;67(4):425–38.
25. Griffin BJ, Worthington EL Jr, Lavelock CR, Greer CL, Lin Y, Davis DE, et al. Efficacy of a self-forgiveness workbook: a randomized controlled trial with interpersonal offenders. J Couns Psychol. 2015;62(2):124–36.
26. Onken LS, Carroll KM, Shoham V, Cuthbert BN, Riddle M. Reenvisioning clinical science: unifying the discipline to improve the public health. Clin Psychol Sci. 2014;2(1):22–34.
27. Kubany ES, Haynes SN, Abueg FR, Manke FP, Brennan JM, Stahura C. Development and validation of the trauma-related guilt inventory (TRGI). Psychol Assess. 1996;8(4):428–44.
28. Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG, et al. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychol Assess. 2018;30(3):383–95.
29. Schnurr PP, Friedman MJ, Lavori PW, Hsieh FY. Design of Department of Veterans Affairs Cooperative Study no. 420: group treatment of post-traumatic stress disorder. Control Clin Trials. 2001;22(1):74–88.
30. Weathers FW, Keane TM, Davidson JR. Clinician-administered PTSD scale: a review of the

- first ten years of research. *Depress Anxiety*. 2001;13(3):132–56.
 31. Schnurr PP, Friedman MJ, Engel CC, Foa EB, Shea MT, Chow BK, et al. Cognitive behavioral therapy for posttraumatic stress disorder in women: a randomized controlled trial. *JAMA*. 2007;297(8):820–30.
 32. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001;16(9):606–13.
 33. Kroenke K, Spitzer R. The PHQ-9: a new depression diagnostic and severity measure. *psychiatric annals*. 2002;32:509–21.
 34. Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: development of a general scale. *Eval Program Plann*. 1979;2(3):197–207.
 35. • Norman SB, Capone C, Panza KE, Haller M, Davis BC, Schnurr PP, et al. A clinical trial comparing trauma-informed guilt reduction therapy (TrIGR), a brief intervention for trauma-related guilt, to supportive care therapy. *Depress Anxiety* (2022). <https://onlinelibrary.wiley.com/doi/abs/https://doi.org/10.1002/da.23244>.
- First randomized controlled trial of TrIGR with 144 post-9/11 veterans. Findings show greater guilt, PTSD symptom, and depression symptom reduction in TrIGR than supportive care therapy.
36. Walters EM, Jenkins MM, Nappi CM, Clark J, Lies J, Norman SB, et al. The impact of prolonged exposure on sleep and enhancing treatment outcomes with evidence-based sleep interventions: a pilot study. *Psychol Trauma*. 2020;12(2):175–85.
 37. Schnurr PP, Chard KM, Ruzek JI, Chow BK, Shih M-C, Resick PA, et al. Design of VA Cooperative Study #591: CERV-PTSD, comparative effectiveness research in veterans with PTSD. *Contemp Clin Trials*. 2015;41:75–84.
 38. McMillan D, Gilbody S, Richards D. Defining successful treatment outcome in depression using the PHQ-9: a comparison of methods. *J Affect Disord*. 2010;127(1–3):122–9.
 39. Derogatis L. Brief symptom inventory 18. MN: Pearson.; 2001.
 40. Skevington SM, Lotfy M, O’Connell KA, WHOQOL Group. The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. *Qual Life Res*. 2004;13(2):299–310.
 41. Erbes CR, Curry KT, Leskela J. Treatment presentation and adherence of Iraq/Afghanistan era veterans in outpatient care for posttraumatic stress disorder. *Psychol Serv*. 2009;6(3):175–83.
 42. Goetter EM, Bui E, Ojserkis RA, Zakarian RJ, Brendel RW, Simon NM. A systematic review of dropout from psychotherapy for posttraumatic stress disorder among Iraq and Afghanistan combat veterans. *J Trauma Stress*. 2015;28(5):401–9.
 43. Mott JM, Mondragon S, Hundt NE, Beason-Smith M, Grady RH, Teng EJ. Characteristics of U.S. veterans who begin and complete prolonged exposure and cognitive processing therapy for PTSD. *J Trauma Stress*. 2014;27(3):265–73.
 44. • Haller M, Norman SB, Davis BC, Capone C, Browne K, Allard CB. A model for treating COVID-19-related guilt, shame, and moral injury. *Psychol Trauma*. 2020.
- This article tackles why moral injury and guilt in particular may be common consequences of the pandemic and a model to use TrIGR to help resolve the resulting distress.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



BEHAVIORAL DISENGAGEMENT MEDIATES THE ASSOCIATION BETWEEN TRAUMA-RELATED GUILT AND MENTAL HEALTH PROBLEMS IN A SAMPLE OF OEF/OIF/OND VETERANS

PRESENTER: CHRISTY CAPONE, PHD

ASSISTANT PROFESSOR OF PSYCHIATRY AND HUMAN BEHAVIOR

BROWN UNIVERSITY


PROVIDENCE VA MEDICAL CENTER

AUTHORS: CHRISTY CAPONE, KAITLYN E. PANZA, MATTHEW T. LUCIANO, ARIEL J.
LANG, & SONYA B. NORMAN



BACKGROUND

- Trauma-related guilt has cognitive and affective components
- It is a common and distressing emotion following a traumatic event, and linked with several mental health problems (e.g., PTSD, depression, substance use)
- Higher rates of suicidality among those with guilt
- Guilt cognitions have been linked to aggressive behavior and violence
- Predicts poorer outcomes in empirically supported therapies (e.g., PE, CPT)
- Recent study concluded that guilt (related to justification) is a common residual symptom after PTSD tx completion (Larsen et al., 2018)



BACKGROUND


- Little is known about the mechanisms underlying these associations
 - Guilt is so aversive that many individuals engage in avoidant forms of coping, including behavioral disengagement (Held, Owens & Anderson, 2015)
 - Behavioral disengagement is conceptualized as the giving up on trying to cope with a stressor and/or pulling away from available resources (Rioli & Savicki, 2010)
- 
- 

THE PRESENT STUDY

We examined cross-sectional associations between trauma-related guilt, behavioral disengagement, and four outcomes:

- PTSD symptom severity
- Depressive symptoms
- SUD diagnosis
- Suicide intensity

We also examined whether behavioral disengagement mediated these relationships in a cross-sectional analysis

The slide features a light blue background with a subtle gradient. In the corners, there are decorative elements resembling circuit board traces or neural network connections, consisting of thin blue lines and small circles.

METHOD

- The sample consisted of 184 veterans who enrolled in a RCT to treat trauma-related guilt stemming from a post 9/11 deployment
 - Baseline data was utilized for the present analyses
- The study was conducted at VA Medical Centers in Providence, RI and San Diego, CA
- Veterans in the sample were reflective of the complex and severe clinical presentation observed in many VA settings

MEASURES AND ANALYSES

- Measures

- Behavioral disengagement -- Brief COPE; Carver, 1997
- Trauma-related guilt -- Trauma-Related Guilt Inventory (TRGI); Kubany et al., 1996
- PTSD symptom severity -- Clinician Administered PTSD Scale (CAPS-5); Weathers et al., 2018
- Depressive symptoms -- Patient Health Questionnaire (PHQ-9); Kroenke et al., 2001
- SUD diagnosis -- Structured Clinical Interview for DSM 5 (SCID-5); First et al., 2002
- Suicide intensity -- Columbia Suicide Severity Rating Scale (C-SSRS); Posner et al., 2008

- Analytic Plan

- We conducted mediation analyses with guilt as the independent variable, behavioral disengagement as the mediator, and three mental health variables as the dependent variables (in three separate models).

RESULTS

Table 1. Demographics

	M (SD) or %
Age	39.14 (SD=8.44)
Gender (Male)	94%
Ethnicity	
Hispanic/Latino	25.3%
Non-Hispanic	63.8%
Declined to Answer	10.9%
Race	
White/Caucasian	69.5%
Black/African American	11.5%
Asian	10.3%
Other Identified Race	9.7%

Table 1. Demographics (Continued)

	M (SD) or %
Number of Deployments	2.01 (SD=1.20)
Branch	
Army	36.7%
Air Force	6.2%
Marines	27.1%
National Guard	5.1%
Navy	24.9%
CAPS-5	37.33 (SD=10.01)
PHQ-9	14.51 (SD=6.39)
C-SSRS	6.37 (SD=7.00)
PTSD Dx	84%
Substance Use Dx	44%


RESULTS

Table 2. Correlations

	1	2	3	4	5	6
1. Trauma-Related Guilt (TRGI)	--					
2. PTSD Severity (CAPS-5)	.45***	--				
3. Depression (PHQ-9)	.31***	.62***	--			
4. Suicide Risk Intensity (C-SSRS)	.23***	.35***	.44***	--		
5. Substance Use Disorder (SCID)	.04	.01	.09	.16*	--	
6. Behavioral Disengagement (B-COPE)	.31***	.33***	.49***	.34***	.21**	--

Note: * $p < .05$; ** $p < .01$; *** $p < .001$; TRGI = Trauma-Related Guilt Inventory; CAPS-5 = Clinician Administered PTSD Scale for DSM-5; PHQ-9 = Patient Health Questionnaire; C-SSRS = Columbia Suicide Severity Rating Scale; SCID = Structured Clinical Interview for DSM-5; B-COPE = Brief Coping Orientation to Problems Experienced Inventory


RESULTS



Note: $***p \leq .001$

Indirect Effect = .94, 95% CI: .36, 1.69


RESULTS



Note: $**p \leq .01$
 $***p \leq .001$

Indirect Effect = .93, 95% CI: .32, 1.63

RESULTS



Note: $*p \leq .05$
 $***p \leq .001$

Indirect Effect = 1.24, 95% CI: .62, 1.93

SUMMARY OF FINDINGS

- Trauma-related guilt was significantly associated with three of the outcomes (PTSD, depression, suicidality) as well as the putative mediator, behavioral disengagement
- Contrary to our hypothesis, SUD diagnosis was not related to trauma-related guilt
- Results of mediation analyses showed that behavioral disengagement mediated the relationship between guilt and suicide intensity, and partially mediated the relationships with PTSD and depressive symptoms

FUTURE DIRECTIONS AND CONCLUSIONS

- Consistent with previous research, trauma-related guilt was related to common posttraumatic mental health problems
- Our findings, though cross-sectional, may help to elucidate how trauma-related guilt may lead to mental health problems
- May also be that mental health issues (e.g., avoidance, mistrust, hopelessness) lead veterans to turn away from help, which in turn causes them to feel guilty
 - Longitudinal research is needed to clarify directionality
- These results highlight a potentially important treatment target and may be particularly relevant to suicide prevention efforts

FUTURE DIRECTIONS AND CONCLUSIONS

- Future research should better understand WHY trauma-related guilt causes veterans to turn away from resources
 - Perhaps because they don't feel like they deserve help? For fear of stigma/judgment?
- Because turning away from helpful resources is associated with strong guilt reactions and mental health issues, it may be important to utilize more opportunistic interventions that can be delivered in other settings (e.g., primary care)
- With 57-85% of the variance in the total effects explained by behavioral disengagement, additional explanatory variables connecting guilt and mental health outcomes should be evaluated



ACKNOWLEDGEMENTS

- This research was funded by the Department of Defense W81XWH-15-1-0330 and W81XWH-15-1-0331 (PIs: Norman and Capone)
- Thank you to the incredible teams at both study sites and to the veterans who participated in this research
- Contact: Christy_Capone@brown.edu

Reintegration Stress Among Post-9/11 Veterans: Relationships with Moral Injury, PTSD Symptoms, and Guilt

Erica Johnson¹, Alexander Kline², Kaitlyn Panza², Brittany Davis³, Christy Capone⁴, Sonya Norman^{2,5,6}

¹VA Northern CA Health Care System, Sacramento, CA

²VA San Diego Healthcare System, San Diego, CA

³James A. Haley Veteran's Hospital, Tampa, FL

⁴Brown University, Providence, RI

⁵National Center for PTSD, White River Junction, VT

⁶University of California San Diego, San Diego, CA.

INTRODUCTION:

- PTSD symptoms have been associated with worse mental health, reintegration stress, and functional outcomes. Both trauma-related guilt and moral injury are associated with worse mental health; and may also negatively impact reintegration difficulties.
- We aim to examine the relationships between MI, PTSD symptoms, trauma-related guilt and reintegration stress in a group of combat Veterans.

METHOD:

- 184 Veterans of post-9/11 conflicts (94% male; mean age 39.1 (SD = 8.4); 62% White) screened for a transdiagnostic guilt intervention study.
- We examined associations among moral injury (Morally Injurious Events Scale; MIES), PTSD symptoms (CAPS-5), trauma-related guilt (Trauma-Related Guilt Inventory; TRGI), and reintegration stress (Military to Civilian-Questionnaire; M2C-Q).
- Multiple regression was used to evaluate the association between PTSD symptoms, trauma-related guilt, and reintegration stress.
- Correlations were used to explore association between morally injurious events and reintegration stress.

RESULTS:

- TRGI and CAPS-5 total scores explained 42% of the variance in M2C-Q, $F(2, 174) = 63.41, p < .001$.
- When entered into the same regression model, CAPS-5 total scores ($\beta = 0.61, p < .001$), but not TRGI ($\beta = 0.09, p = 0.16$), was significantly associated with M2C-Q.
- Correlations between MIES and M2C-Q found a positive association between all forms of MI including transgressions by others ($r = 0.20, p = .01$), transgressions by self ($r = 0.36, p < .001$), and betrayal ($r = 0.16, p = 0.03$).

DISCUSSION:

- PTSD symptoms were associated with greater reintegration stress. Trauma-related guilt was not found to uniquely contribute to reintegration stress when accounting for PTSD symptoms.
- Morally injurious events were associated with greater reintegration stress.
- Future research is needed to further explore how MI and PTSD symptoms impact reintegration stress and the relationship between MI and PTSD with specific reintegration domains.
- It is of interest how the construct of shame, rather than guilt, may impact reintegration stress.
- Limitations include the use of cross-sectional data. The sample consists of primarily white males, and only post 9/11 era Veterans. As such, results may not generalize.

PTSD symptoms and experiencing morally injurious events are related to increased reintegration stress.

Means and Correlations of MI and Reintegration Stress

Variable	<i>M</i>	<i>SD</i>	1	2	3	4
1. Reintegration Stress	2.12	0.89	-			
2. Transgressions by self	15.83	7.09	0.36**	-		
3. Transgressions by others	9.27	3.09	0.20**	0.64**	-	
4. Betrayal	10.83	4.99	0.16**	0.48**	0.38**	-

* $p < .05$, ** $p < .01$

PTSD symptoms were associated with reintegration stress ($\beta = 0.61, p < .001$), whereas trauma-related guilt was not ($\beta = 0.09, p = 0.16$).



Trauma Informed Guilt Reduction (TrIGR) therapy for guilt, shame, and moral injury resulting from trauma: Rationale, design, and methodology of a two-site randomized controlled trial

Christy Capone, PhD^{a,b*}

^a Providence VA Medical Center, 830 Chalkstone Ave, Providence, Rhode Island 02908 USA

^b Department of Psychiatry and Human Behavior, Center for Alcohol and Addiction Studies, Warren Alpert School of Medicine, Brown University, Providence, Rhode Island, USA

Sonya B. Norman, PhD^{c,d,e*}

^c National Center for PTSD, Executive Division, VA Medical Center, 215 North Main Street, White River Junction, VT 05009 USA

^d VA Center of Excellence for Stress and Mental Health; Veterans Affairs San Diego Healthcare System, Research Service (MC116B), 3350 La Jolla Village Dr, San Diego CA 92161 USA

^e University of California, San Diego, Department of Psychiatry, 9500 Gilman Drive, San Diego, CA 92093, USA

Moir Haller, PhD^{e,f}

^e University of California, San Diego, School of Medicine, Department of Psychiatry, 9500 Gilman Drive, San Diego, CA 92093, USA

^f Veterans Affairs San Diego Healthcare System, Research Service (MC116B), 3350 La Jolla Village Dr, San Diego CA 92161 USA

Brittany Davis, PhD^{g,h}

^g James A. Haley Veterans Hospital, 13000 Bruce B. Downs Blvd., Tampa, FL 33612 USA

^h Department of Psychiatry and Behavioral Neurosciences, University of South Florida, 3515 E. Fletcher Ave, Tampa FL 33613 USA

M. Tracie Shea, PhD^{a,i}

^a Providence VA Medical Center, 830 Chalkstone Ave, Providence, Rhode Island 02908 USA

ⁱ Department of Psychiatry and Human Behavior, Warren Alpert School of Medicine, Brown University, Providence, Rhode Island, USA

Kendall Browne, PhD^{j,k,l}

^j Center of Excellence in Substance Addiction Treatment and Education, Corporal Michael J. Crescenzo VA Medical Center; 21 S. University Ave, Philadelphia, PA 19104 USA

^k Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Health Care System, 1660 S. Columbian Way, MC: S-116-ATC, Seattle, WA 98136 USA

^l Department of Psychiatry & Behavioral Sciences, University of Washington, 1959 NE Pacific St, Seattle, WA 98195 USA

Ariel J. Lang, PhD, MPH^{e,f}

^eUniversity of California, San Diego, School of Medicine, Department of Psychiatry, 9500 Gilman Drive, San Diego, CA 92093, USA

^fVeterans Affairs San Diego Healthcare System, Research Service (MC116B), 3350 La Jolla Village Dr, San Diego CA 92161 USA

Paula P. Schnurr, PhD^{c,m}

^cNational Center for PTSD, Executive Division, VA Medical Center, 215 North Main Street, White River Junction, VT 05009 USA

^mDepartment of Psychiatry, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756 USA

Shahrokh Golshan, PhD^{e,f}

^eUniversity of California, San Diego, School of Medicine, Department of Psychiatry, 9500 Gilman Drive, San Diego, CA 92093, USA

^fVeterans Affairs San Diego Healthcare System, Research Service (MC116B), 3350 La Jolla Village Dr, San Diego CA 92161 USA

Niloofar Afari, PhD^{d,e}

^dVA Center of Excellence for Stress and Mental Health; Veterans Affairs San Diego Healthcare System, Research Service (MC116B), 3350 La Jolla Village Dr, San Diego CA 92161 USA

^eUniversity of California, San Diego, Department of Psychiatry, 9500 Gilman Drive, San Diego, CA 92093, USA

James Pittman, PhD, LCSW^{d,e}

^dVA Center of Excellence for Stress and Mental Health; Veterans Affairs San Diego Healthcare System, Research Service (MC116B), 3350 La Jolla Village Dr, San Diego CA 92161 USA

^eUniversity of California, San Diego, Department of Psychiatry, 9500 Gilman Drive, San Diego, CA 92093, USA

Carolyn B. Allard, PhD, ABPP^{f,n}

^fVeterans Affairs San Diego Healthcare System, Research Service (MC116B), 3350 La Jolla Village Dr, San Diego CA 92161 USA

ⁿCalifornia School of Professional Psychology at Alliant International University, 10455 Pomerado Rd, San Diego CA 92131 USA

Laura Westendorf, MPH^f

^fVeterans Affairs San Diego Healthcare System, Research Service (MC116B), 3350 La Jolla Village Dr, San Diego CA 92161 USA

Author Notes

Correspondence concerning this article should be addressed to Dr. Christy Capone, Mental Health and Behavioral Sciences Service (MHBSS), Department of Veterans Affairs Medical Center, 830 Chalkstone Ave (116B), Providence RI 02908.

Email: christy_capone@brown.edu.

*Dr. Christy Capone and Dr. Sonya Norman are co-first authors of this article.

Abstract

Guilt, shame, and moral injury (MI) are common reactions following exposure to traumatic events and are associated with greater severity of several mental health problems, including posttraumatic stress disorder (PTSD), depression, increased risk of suicidal ideation and poorer psychosocial functioning. Trauma-Informed Guilt Reduction (TrIGR) is a transdiagnostic psychotherapy to address guilt, shame, and MI stemming from traumatic events. The primary goals of TrIGR are to help patients accurately appraise their trauma and to re-engage with their values in order to lead a more meaningful life. This paper presents the rationale, design, and methodology of a two-site randomized controlled trial (RCT) examining the efficacy of TrIGR compared to Supportive Care Therapy (SCT) in a sample of U.S. veterans ($N = 145$) who endorse guilt related to a traumatic event that occurred during military deployment. This study is the first RCT powered to investigate TrIGR's efficacy on reducing posttraumatic guilt, as measured by the Trauma Related Guilt Inventory (TRGI), in comparison to an active control condition. In addition, the study will examine a range of secondary and exploratory outcomes including shame, quality of life, suicidal ideation, substance use, and PTSD and depression symptoms. Findings from this efficacy study will be essential in informing future efficacy and effectiveness trials.

Keywords: trauma, guilt, shame, psychotherapy, veterans

1. Introduction

Guilt, shame, and moral injury (MI) are common following traumatic events (e.g., Friedman et al., 2011). Guilt arises when trauma survivors blame their actions or inactions for all or part of the trauma (i.e., “If I had done x instead of y, my fellow soldier would be alive”) (Kubany & Watson, 2003). Shame is when trauma survivors judge not just their actions but their entire self as bad or damaged because of their role in the trauma (i.e., “I am a bad person” or “I’m damaged goods”) (Tangney, Stuewig, & Mashek, 2007). MI refers to the painful emotional aftermath of experiences where someone acted or witnessed acts that went against deeply held morals or values and is characterized by strong reactions of guilt and shame (Litz et al., 2009; Griffin et al., 2019). In addition to causing emotional distress, posttraumatic guilt, shame, and MI are risk factors for greater severity of several mental health problems, including posttraumatic stress disorder (PTSD), depression, suicidal ideation, and poorer psychosocial functioning (Browne et al., 2015; Bryan et al., 2018; Griffin et al., 2019; Koenig et al., 2018; Marx et al., 2010; Norman et al., 2018).

In the latest Diagnostic and Statistical Manual (DSM-5; American Psychiatric Association, 2013), guilt and shame were included in the diagnostic criteria for PTSD for the first time and, in recognition of the many ways PTSD may present, the diagnosis is no longer considered an anxiety disorder. These changes facilitate the examination of different PTSD phenotypes, such as one characterized by guilt and shame, and raise the possibility that different phenotypes may respond better to specific treatments. Trauma-related guilt is one of the symptoms most likely to persist after successful PTSD treatment (Larsen, Fleming & Resick, 2019; Kubany et al., 2004), suggesting intervention targeting posttraumatic guilt may be warranted. Also critical is that not all who experience trauma-related guilt, shame, or MI have

PTSD. Posttraumatic distress presents in many forms, including depression and suicidality, arguing for transdiagnostic interventions that reach across disorders. However, to date, most treatments for posttraumatic psychological health have been primarily disorder specific, most commonly PTSD (Lang et al., 2012).

For these reasons, we developed Trauma-Informed Guilt Reduction (TrIGR), a brief transdiagnostic psychotherapy to address guilt, shame, and MI from traumatic events (Norman et al., 2019; Norman, Wilkins, Myers & Allard, 2014). Because trauma survivors often overestimate how much control they had during a traumatic event, TrIGR helps survivors consider what they truly knew and were capable of doing at the time (Kubany et al., 2004). TrIGR helps patients identify and re-engage with values (particularly those that may have been violated during the trauma). The goal is for patients to understand the full context of their traumatic experience and develop positive ways to express values rather than through suffering. This paper presents the rationale, design, and methodology of an RCT to examine TrIGR compared to Supportive Care Therapy (SCT) in veterans who endorse guilt from a traumatic event during deployment.

1.1 Research objectives and hypotheses

The primary objective of this study is to evaluate the efficacy of TrIGR in reducing trauma-related guilt in a sample of veterans who served in military operations following the 9/11 terrorist attacks. Our primary hypothesis is that veterans receiving TrIGR, compared to those receiving SCT, will report significantly greater reductions in guilt severity at the end of treatment and at follow-up. A secondary aim of this study is to examine TrIGR's effects on shame and quality of life. Accordingly, our secondary hypothesis is that veterans in the TrIGR group will exhibit greater reductions on measures of shame as compared to the SCT group, and greater

improvement in their quality of life at the end of treatment and at follow-up. By including veterans with a variety of post-deployment mental health problems, we are able to conduct exploratory analyses to examine TrIGR's effects on PTSD and depressive symptom severity, suicidal ideation, and alcohol/substance use. At the time the study was initiated, we were not able to identify a validated measure of change in MI through treatment. However, we were able to measure MI experiences related to deployment using a validated assessment and will therefore be able to evaluate how such experiences relate to posttraumatic guilt and shame.

2. Materials and methods

2.1 Research design

This is a prospective, randomized, controlled trial designed to assess the efficacy of TrIGR as compared to an active control (SCT) for the treatment of guilt related to a traumatic event that occurred during deployment among male and female veterans. Both treatment conditions involve individual therapy delivered in weekly sessions. After providing written informed consent, all eligible participants complete an in-person baseline assessment, receive 6 sessions of TrIGR or SCT, with weekly measures related to the primary and secondary aims, and complete follow-up assessments immediately post-treatment, and 3- and 6-months later.

2.2 Participants

A total of 145 participants will be enrolled across two study sites –VA Medical Centers in San Diego, CA, and Providence, RI. Participants are randomized by the study statistician at the individual level using masked allocation, stratified by site and gender. Inclusion criteria are as follows: (1) having been deployed during Operation Enduring Freedom (OEF), Operation Iraqi Freedom (OIF), or Operation New Dawn (OND); (2) endorsing trauma-related guilt as indicated by a score of 2 or higher ("true" to "extremely true") on at least one item measuring

guilt severity or scoring 2 or higher ("true" to "extremely true") on at least one guilt cognition (hindsight bias/responsibility, wrongdoing, or lack of justification) on the Trauma Related Guilt Inventory (TRGI; Kubany et al., 1996); (3) English literacy; (4) intention to stay in the local area during study participation; and (5) if meeting diagnostic criteria for mild or moderate alcohol or substance use disorder, willingness to set goals to reduce use.

Exclusion criteria are kept to a minimum in order to maximize generalizability of the findings and included only factors that would impede study participation: (1) moderate or severe cognitive impairment on the Montreal Cognitive Assessment (MoCA; Nasreddine et al., 2005); (2) acute risk of suicide; (3) severe substance use disorder in the past two months; (4) current psychosis or mania; (5) residence greater than 50 miles from the nearest study site; (6) life threatening or unstable medical illness, and (7) currently receiving trauma-focused treatment (those currently in treatment could qualify following completion).

Veterans with mild to moderate alcohol and substance use disorders, suicidal ideation without acute risk of suicide, and anxiety and depressive disorders are not excluded due to the high co-occurrence with posttraumatic guilt. Those with mild cognitive impairment are not excluded given research showing that individuals with mild to moderate traumatic brain injury (TBI) can benefit from cognitive behavioral treatments (Chard et al., 2011).

We allow participants to continue to engage in treatment as usual (TAU), other than trauma-focused treatments, as we do not expect TrIGR to be a stand-alone treatment for disorder specific conditions. Participants may continue receiving substance use and mental health treatment as needed, including pharmacotherapy. However, we exclude veterans who are currently receiving other trauma focused treatment such as Prolonged Exposure (PE) or Cognitive Processing Therapy (CPT) as these PTSD treatments may also address guilt and

shame. All treatment received during the treatment and follow-up phases of the study is carefully tracked during the post-treatment assessment, including types of psychotherapy and medication. If counts of specific types of treatments received differ significantly across sites or conditions, we will include that variable as a fixed effect in subsequent data analyses.

2.3 Study procedures

The study procedures were reviewed and approved by the Institutional Review Boards (IRBs) at VA San Diego Healthcare System, Providence VA Medical Center, Brown University, and the Human Research Protections Office (HRPO) at the Department of Defense.

Recruitment and Screening. Study participants are recruited through referrals from clinicians at both study sites, and through self-referral in response to advertisements posted in public areas throughout the medical centers. Project coordinators contact interested veterans and conducted a brief phone screening to assess for broad eligibility (e.g., service era). If an interested veteran meets preliminary eligibility criteria, he or she is invited to attend an in-person visit during which written informed consent is obtained and the baseline assessment is completed. Data collection for this study began in June 2016 and is expected to be completed in December 2020.

Assessment Procedures. Semi-structured interviews are conducted by trained assessors (bachelor- masters- or doctoral-level) who are blind to the treatment condition of the participants. Assessor training involves completing the National Center for PTSD online CAPS-5 training and additional training with a study co-investigator, scoring standardized mock assessments to high inter-rater reliability, shadowing other assessors, and completing a minimum of 3-4 assessments in the presence of an experienced assessor to allow for feedback. Training for the Timeline Follow-back for substance use and the Columbia-Suicide Severity Rating Scale for suicidal

ideation and behaviors include observation of an experienced assessor followed by role playing and then administering the assessments under live supervision until fidelity is achieved.

Self-report measures are completed via the VA eScreening program, a secure electronic platform for collection of self-report data developed at the VA Center of Excellence for Stress and Mental Health (Pittman et al, 2017). eScreening provides customized and automated data collection by presenting assessment items for veterans to answer on a mobile tablet (iPad). eScreening has built-in protections against missing data, as well as algorithms for automated scoring of common questionnaires. For this study, sociodemographic questions and the self-reported primary, secondary, and exploratory outcome measures were programmed into eScreening. Participants at both sites use an iPad connected to the VA secure WiFi to complete the relevant measures at each assessment time point. The data are collected using an individual study ID and stored on a VA secure server and accessible by the study team. Overall, the time spent collecting clinical interview and self-report data at baseline is approximately three hours; two hours for follow-up assessments.

2.4 Measures

Primary Outcome. The primary outcome measure for this study is the TRGI, a 32-item, validated, self-report questionnaire assessing traumatic guilt related to an index event. The TRGI has three scales – Global Guilt, Distress, and Guilt Cognitions; the Guilt Cognitions scale has three subscales (Hindsight Bias/Responsibility, Lack of Justification, and Wrongdoing). Change in global Guilt (which includes items assessing frequency and severity of guilt with scores ranging from 0 to 4) will be the primary outcome of interest. We will also examine clinically meaningful change using previously established criteria of reduction from above 1.75 to 1.0 or less (Nishith, Nixon, & Resick, 2005). Participants are instructed to reference the same event at

each timepoint when completing the TRGI. Internal consistency is high for the TRGI (guilt severity = .90, distress = .86, guilt cognitions = .86; Kubany et al., 1996).

Secondary Outcomes. The Internalized Shame Scale (ISS; Cook et al., 2001) is a 30-item self-report measure assessing shame proneness scored on a 5-point Likert scale. The ISS yields sum scores for two subscales, self-esteem and internalized shame, and has been well-validated with research and clinical populations. The Trauma Related Shame Inventory (TRSI; Øktedalen, Hagtvét, Hoffart, Langkaast, & Smucker, 2014) is a 24-item self-report measure assessing trauma-related shame on a 4-point Likert scale with internal and external shame subscales. The World Health Organization Quality of Life (WHO-QOL-BREF; WHOQOL Group, 1998) is a 26-item measure of quality of life across four domains: physical, psychological, social relationships, and environment. The WHO-QOL-BREF has excellent internal validity and test-retest reliability.

Exploratory Outcomes. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5; Weathers et al., 2018) is a semi-structured interview used to assess PTSD diagnostic criteria and severity. The CAPS-5 assesses each of the 20 items from the DSM-5 criteria B, C, D, and E and has demonstrated high levels of internal consistency, good interrater reliability, and excellent convergent validity. The CAPS-5 can be administered in about 60 minutes, and it has the advantages of categorical (diagnostic) or continuous scoring of PTSD. The CAPS-5 is administered at baseline and at each of the follow-ups post-treatment.

The PTSD Checklist-5 (PCL-5; Weathers et al., 2013) is a self-report instrument that assesses PTSD symptom severity. It consists of 20 items, scored on a 5-point scale (0 = not at all to 5 = extremely), that correspond to the DSM-5 symptoms of PTSD. Research demonstrates sound psychometric properties of the PCL-5 for use with military veterans (Bovin et al., 2016).

The Patient Health Questionnaire (PHQ-9; Kroenke & Spitzer, 2002) is a self-report scale assessing common symptoms of depression. The PHQ-9 is among the most widely used self-report depression measure in clinical populations and has demonstrated strong diagnostic validity and sensitivity (Spitzer et al., 1999).

The Timeline Follow-back (TLFB; Sobell & Sobell, 1992) is utilized at all assessment points to assess alcohol and other substance use during the 90 days preceding each interview. The Quantity-Frequency Index (Q-F; Room, 1990) will be calculated for alcohol use; drug use indices will be similarly derived for opioids, cannabis, and other substances. The TLFB is used at each follow-up to establish percent days heavy drinking (PDHD), percent days abstinent (PDA), and current alcohol/drug use pattern. The TLFB is considered a gold standard interview for gathering retrospective self-report data on alcohol use and its reliability regarding other substance use is well established (Robinson et al., 2014).

The Columbia-Suicide Severity Rating Scale (C-SSRS; Posner et al., 2008) is a clinician-administered interview designed to track suicidality during a treatment trial and covers the wide spectrum of suicidality including ideation and intent. The C-SSRS has demonstrated sound psychometrics with respect to validity as well as sensitivity and specificity for suicidal behavior classification (Posner et al., 2011). For the present study, the C-SSRS assesses suicidality over the past 3 months at baseline, and since the previous assessment at all follow-ups.

To assess MI experiences, participants complete the Moral Injury Events Scale (MIES; Nash et al., 2013) at baseline. The MIES asks whether participants endorse any of nine potentially morally injurious events or beliefs that occur in wartime. Participants respond on a 6-point Likert scale (strongly agree to strongly disagree). The scale shows strong internal, discriminant, and concurrent validity and strong test re-test reliability (Nash et al., 2013).

2.5 Treatment conditions

Trauma Informed Guilt Reduction (TrIGR). TrIGR is delivered over six 90-minute individual sessions (see Table 1). The first module (delivered over 2 sessions) includes an overview of common reactions to trauma and provides psychoeducation regarding posttraumatic guilt, shame, and MI. The Non-Adaptive Guilt and Shame (NAGS) model that underlies TrIGR (see Norman et al., 2014) is reviewed along with common sources of deployment-related traumatic guilt and shame (Kubany, 1994), such as taking part in or witnessing atrocities, being unable to prevent a traumatic event, or surviving when a someone else was killed. Module 2 (delivered over 2 sessions) uses cognitive restructuring to help participants evaluate four types of cognitive errors contributing to posttraumatic guilt identified in prior research (Kubany et al., 2004). These cognitive errors include hindsight-bias (believing that the outcome was known at the time of the trauma), lack of justification (believing there was no or little justification for the course of action one chose to take), responsibility (believing one was solely or mostly responsible for the traumatic event), and wrongdoing (believing one purposely did something that was wrong or violated important values). The TrIGR protocol allows for more than one traumatic event to be processed if indicated.

Module 2 concludes with a discussion regarding the function of guilt and shame in the patient's life (e.g., "It's my duty to remember how my buddy died" or "If I didn't feel bad about it I would really be a bad person"), and what it would be like to feel less guilt/shame going forward. This discussion helps to identify values that were violated during the trauma which allows for the transition to Modules 3 and 4 (one session each) where the focus is on identifying the patient's values and setting goals to live a more value-driven life. Positive ways to express

values rather than through guilt and shame are discussed with an aim of setting goals toward value driven growth. Norman and colleagues (2014) describe the protocol in more detail.

Supportive Care Therapy (SCT). SCT is a present-centered, non-directive therapy that emphasizes principles of unconditional positive regard, genuineness, and empathic understanding. The manual used in this study is based on the supportive components of Present Centered Therapy (PCT; Shea et al., 2003) but excludes the problem solving component and daily diary usually included in PCT. SCT is delivered in six sessions, approximately 90 minutes each, in order to parallel the dose of TrIGR. Following the initial session during which psychoeducation regarding common trauma reactions to trauma and guilt, participants are free to choose the content of each session. If participants elect to discuss their traumatic experience or feelings of guilt, therapists respond to this as they would any other content area – with a validating and nonjudgmental stance while gently redirecting to present-focused content. Therapists are explicitly instructed not to provide advice, assign activities, or engage in strategies and techniques employed in TrIGR or other evidenced-based interventions. At the end of each session, the therapist offers an integrative summary of the session’s content and process. The rationale for using SCT is to provide a credible therapeutic comparison condition to TrIGR (see Shea et al., 2020). SCT controls for the nonspecific aspects that characterize most forms of therapy and are distinct from the hypothesized active mechanisms of TrIGR.

2.6 Training and supervision of study therapists

Therapists are masters or doctoral level trainees or licensed mental health providers (psychologists, mental health counselors) who deliver both therapy conditions. Co-investigators train study therapists on both TrIGR and SCT using didactics, videos, audio recordings, and role plays. Therapists are supervised via audio recordings of therapy sessions and participation in

weekly clinical supervision meetings. Supervisory psychologists listen to all sessions for therapists' first two cases; thereafter, 10 percent of sessions are listened to for treatment adherence.

Treatment Fidelity. Our approach to treatment fidelity and adherence utilizes accepted standards including: (1) using treatment manuals with weekly objectives, outcomes, and agendas; (2) therapist training (to avoid bias, therapists are trained to deliver both interventions); and (3) ongoing evaluation of treatment fidelity through review of audio-recording of therapy sessions and weekly supervision. A member of the study team provides ratings on 10% of the audio-recorded sessions randomly selected by the study statistician. Finally, therapists keep a session-by-session tracking form that included self-ratings about the “% of time” of each session spent “using the manual” and covering the relevant module content.

2.7 Data analytic plan

All participants will be included in the analyses (intent to treat) regardless of the amount of treatment they received. Successful randomization will be assessed by performing a series of analysis of variance (ANOVA), Wilcoxon-rank sum tests, χ^2 or Fisher's exact tests to compare the groups on demographic and initial baseline clinical characteristics. Our data analysis methods are robust with respect to missing data and dropout; nonetheless, we will use pattern-mixture modeling to detect bias due to drop out or missing data according to procedures detailed by Hedeker and Gibbons (1997).

2.8 Primary outcome analyses

We hypothesized that participants in TrIGR, compared to participants in SCT, will report significantly greater reductions in guilt severity (as indicated by the TRGI) at the end of treatment and the follow-up period. This hypothesis will be tested using mixed effects models.

Specifically, we will examine random regression models (RRM) and mixed model analysis of variance (MMANOVA). RRM assumes that change over time is linear while MMANOVA considers time as a categorical classification variable and does not assume any specific profile between the outcome variable and time. Each outcome variable will be graphed versus time for each subject to evaluate what function of time best describes the data. If the change is linear, we will proceed with the RRM structure. If the time pattern is not immediately apparent, we will proceed with the MMANOVA. A fully saturated treatment x time model will be utilized for inference. Co-variance structure will be chosen based on Akaike's Information Criterion (AIC). Random group level treatment effects will also be evaluated for importance based on the model AIC.

Responses at baseline through the 6-month follow-up will be nested within subjects. Slope (change in outcome over time) will be entered into the model as a random factor and interacted with treatment group. Intercept and slope will be modeled as random effects nested within subject, and treatment group will be a fixed effect. If needed based on preliminary analyses, baseline covariates (e.g., demographics) will also be entered as fixed effects. Site and the treatment x site interaction will be included as "nuisance parameters;" that is, they will be included to account for possible overall site effects or possible site differences in treatment effects. To test our secondary and exploratory hypotheses, we will use a similar data analysis strategy (i.e. mixed effects models) as for our primary aim.

2.9 Power analysis

Overall, assumptions for our sample size estimation are: (1) sufficient power to test different hypotheses using different analytical models; (2) the reality of recruiting subjects and conducting the study; (3) project cost considerations; and (4) study duration. Therefore, for

Hypotheses 1 and 2, we performed our calculations using several different methods (e.g., Hedeker & Gibbons, 1999) and selected a sample size that provided us with a minimum of 80% power for medium to large effect sizes in each case. To detect a medium effect size with 80% power and a two-tailed alpha of .05 would require a sample size of 59 participants per group. The addition of 12 participants per group would account for up to 20% attrition at $p = .05$. Thus, a total sample size of 145 subjects provides us with a minimum of 80% power to detect the medium effect size for our primary hypothesis and 80% for our secondary hypothesis. The minimum power estimation is based on sample size calculation for 10% to 20% attrition, correlations of 0.2, 0.5, and 0.8 between the repeated measures, and for medium and large effect sizes.

3. Discussion

This paper reviews the rationale, design, and methodology of a two-site RCT examining the efficacy of TrIGR, as compared to SCT, in reducing trauma-related guilt, shame, and common posttraumatic mental health problems. Given the significant associations among posttraumatic guilt, shame, MI and multiple mental health problems, we developed TrIGR as a transdiagnostic treatment, rather than a disorder-specific intervention, based on an underlying model that non-adaptive guilt and shame (NAGS) contribute to the development and severity of multiple forms of posttraumatic psychiatric distress and impairment (Norman et al., 2019; 2014). The current study gives us the opportunity to test aspects of the NAGS model, including the role of reducing guilt and shame in reducing common posttraumatic problems.

The trial described here is the first to our knowledge to take a transdiagnostic approach to examining the effects of addressing guilt and shame in treatment across the spectrum of diagnoses and functional problems commonly associated with trauma. Evaluating interventions

to address trauma-related guilt, shame and MI is important for a number of reasons. First and foremost, we will be able to evaluate whether treating these is an effective way to reduce distress and impairment across a number of diagnoses commonly associated with trauma. Second, trauma-related guilt and shame do not always respond to current effective treatments for PTSD, even when treatment is otherwise successful (Larsen, Fleming & Resick, 2019). Guilt, shame, and MI are also associated with greater depression symptom severity, substance use, and suicidal ideation (Bryan et al., 2015; Bryan et al., 2018; Griffin et al., 2019; Koenig et al., 2018; Wilkins et al., 2013), but treatments for these problems typically do not include processing of traumatic events that give rise to these emotions. Processing traumatic events is a key component of the most highly recommended treatments for posttraumatic distress (VA/DoD, 2017). Additionally, the self-medication hypothesis suggests that substance use may begin in an effort to cope with and ameliorate emotional distress following trauma, including guilt and negative affect (Brown & Wolfe, 1994; Khantzian, 1985), resulting in a cycle of negative reinforcement. If avoidance of and distress related to guilt, shame and MI are contributing to alcohol and other substance use, resolution or amelioration of these may help alcohol/substance use treatment to be fully effective. Finally, while evidence-based treatments for PTSD can reduce posttraumatic guilt and be effective when MI is present (e.g., Clifton, Feeny, & Zoellner, 2017; Resick et al., 2002; Held et al., 2018), additional effective methods will add value when using shared decision making with patients and in having additional options when a particular treatment is not desired or did not prove to be effective for reducing guilt.

Studying a treatment for a transdiagnostic mechanism rather than for a specific diagnosis (i.e., PTSD) raised some unique design considerations. We contemplated having PTSD symptom severity as our primary outcome as this is a measure familiar to those studying posttraumatic

reactions and we anticipated that most participants would have significant PTSD symptoms even if they did not have the full diagnosis. However, since there was a well validated measure of trauma-related guilt and this was the primary target of the intervention, we elected to use the TRGI as our primary outcome measure. We measure PTSD symptoms as an exploratory outcome and will have the opportunity to examine the relationship between change in guilt and change in PTSD symptoms. We similarly considered whether PTSD symptoms needed to be part of the study inclusion criteria as an additional marker of posttraumatic distress. We ultimately decided to require only criterion A of the PTSD diagnosis (i.e., that participants had guilt from a traumatic event that met the DSM-5 definition), since TrIGR is designed for trauma-related guilt. We made this decision because we wanted to study TrIGR's efficacy for a variety of posttraumatic presentations.

If our hypotheses are supported, findings from this efficacy study will be important in informing future efficacy and effectiveness trials, including examination of TrIGR compared with other trauma focused treatments such as PE or CPT, with treatments for other comorbid disorders, for other treatments of moral injury, and with non-military traumas. Generalizability will also be important to examine in future research. Guilt and shame, long part of the diagnostic criteria for depression, were added to DSM-5 in recognition that they often occur following a wide variety of trauma types (Friedman et al., 2011). Examples of guilt, shame, and MI-inducing events outside of military experiences could include killing someone in a motor vehicle accident or exposing children to an abusive situation. An example that is highly relevant to the current COVID-19 pandemic involves healthcare workers (Campbell, Ulrich & Grady, 2016; Greenberg, Docherty, Gnanapragasam & Wessely, 2018) who cared for patients and may be at risk for subsequent guilt, shame, or MI. They may feel guilty about not being able to save a patient's life,

surviving while others died, or infecting others, even if they did the best they could under unprecedented and difficult circumstances. If TrIGR is effective in reducing guilt and shame in the current study, it would be valuable to evaluate it with healthcare workers who experience guilt and shame from such events (Haller et al., 2020).

Further research can examine TrIGR's effectiveness both prior to and following other interventions for posttraumatic distress and be used to develop guidance regarding sequencing of TrIGR relative to other treatments. For those who continue to experience distress related to guilt and shame after completing disorder specific empirically supported treatments, TrIGR may be an effective tool for continued focus and processing of these emotions. Conversely, it is possible that for patients who may not want to engage in a longer treatment, TrIGR may be a gateway to the next step of treatment. For some presenting with posttraumatic guilt, shame, and MI, no further treatment may be needed. Such research will help determine sequencing of TrIGR with other interventions, when TrIGR may be useful after disorder specific interventions, and when TrIGR may be most appropriate as a first line treatment.

In summary, TrIGR is a brief, transdiagnostic intervention based on a cognitive behavioral model. It targets a common and impairing source of posttraumatic distress. If shown to be effective, these factors will make TrIGR potentially useful to many patients with trauma-related and other disorders, and easy to disseminate in the VA Healthcare System, to active duty mental health providers, and across a variety of healthcare settings.

Funding

This research was supported by award numbers W81XWH-15-1-0331 (CC) and W81XWH-15-1-0330 (SN) from the U.S. Department of Defense.

Role of the funding source

The funding source had no involvement in the study design, the collection, analysis and interpretation of the study data, or the decision to submit this report for publication.

Conflicts of Interest

Some of the authors (CC, SN, BD, KB, and CA) earn royalties from Elsevier Press.

References

- American Psychiatric Association. (2013). *Diagnostic and Statistical Manual of Mental Disorders* (5th ed.). Washington, DC: Author.
- Bannister, J. A., Colvonen, P. J., Angkaw, A. C., & Norman, S. B. (2019). Differential relationships of guilt and shame on posttraumatic stress disorder among veterans. *Psychological Trauma: Theory, Research, Practice, and Policy*, 11(1), 35–42. <https://doi.org/10.1037/tra0000392>
- Bovin, M. J., Marx, B. P., Weathers, F. W., Gallagher, M. W., Rodriguez, P., Schnurr, P. P., & Keane, T. M. (2016). Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (PCL-5) in veterans. *Psychological Assessment*, 28(11), 1379-1391. doi: [10.1037/pas0000254](https://doi.org/10.1037/pas0000254)
- Bryan, C. J., Bryan, A. O., Roberge, E., Lefker, F. R., & Rozek, D. C. (2018). Moral injury, posttraumatic stress disorder, and suicidal behavior among National Guard personnel. *Psychological Trauma: Theory, Research, Practice, and Policy*, 10(1), 36–45. doi: [10.1037/tra0000290](https://doi.org/10.1037/tra0000290)
- Bryan, C. J., Morrow, C.E., Etienne, N., & Ray-Sannerud, B (2013). Guilt, shame, and suicidal ideation in a military outpatient clinical sample. *Depression and Anxiety*, 30, 55-60. doi: [10.1002/da.22002](https://doi.org/10.1002/da.22002)
- Bryan, C. J., Roberge, E., Bryan, A. O., Ray-Sannerud, B., Morrow, C. E., & Etienne, N. (2015). Guilt as a mediator of the relationship between depression and posttraumatic stress with suicide ideation in two samples of military personnel and veterans. *International Journal of Cognitive Therapy*, 8, 143-155. <https://doi.org/10.1521/ijct.2015.8.2.143>

- Brown, P.J. & Wolfe, J. (1994). Substance abuse and post-traumatic stress disorder comorbidity. *Drug and Alcohol Dependence*, 35, 51-59. [https://doi.org/10.1016/0376-8716\(94\)90110-4](https://doi.org/10.1016/0376-8716(94)90110-4)
- Browne, K.C., Trim, R.S., Myers, U.S., & Norman, S.B. (2015). Trauma-related guilt: Conceptual development and relationship with posttraumatic stress and depressive symptoms. *Journal of Traumatic Stress*, 28, 134-141. doi: [10.1002/jts.21999](https://doi.org/10.1002/jts.21999)
- Campbell, S.M., Ulrich, C.M. & Grady, C. (2016). A Broader Understanding of Moral Distress. *The American Journal of Bioethics*, 16(12), 2-9. doi: [10.1080/15265161.2016.1239782](https://doi.org/10.1080/15265161.2016.1239782)
- Chard, K.M., Schumm, J.A., McIlvain, S.M., Bailey, G.W., & Parkinson, R.B. (2011). *Exploring the efficacy of a residential treatment program incorporating cognitive processing therapy-cognitive for veterans with PTSD and traumatic brain injury*. *Journal of Traumatic Stress*, 24(3), 347-351. doi: [10.1002/jts.20644](https://doi.org/10.1002/jts.20644)
- Clifton, E.G., Feeny, N.C., & Zoellner, L.A. (2017). Anger and guilt in treatment for chronic posttraumatic stress disorder. *Journal of Behavior Therapy and Experimental Psychiatry*, 54, 9-16. doi: [10.1016/j.jbtep.2016.05.003](https://doi.org/10.1016/j.jbtep.2016.05.003)
- Cook, D.R., Kostecki-Dillon, T., Wilson, W., & Coccimiglio, J. (2001). *Internalized shame scale: Technical manual*. Multi-Health Systems.
- Department of Veterans Affairs/Department of Defense. (2017). *VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress*. Retrieved from <https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal.pdf>
- Friedman, M.J., Resick, P.A., Bryant, R.A., & Brewin, C.R. (2011). Considering PTSD for DSM-5. *Depression and Anxiety*, 28(9), 750-769. doi: [10.1002/da.20767](https://doi.org/10.1002/da.20767)

- Griffin, B.J., Purcell, N., Burkman, K., Litz, B.T., Bryan, C.J., Schmitz, M., Villierme, C., Walsh, J., & Maguen, S. (2019). Moral injury: An integrative review. *Journal of Traumatic Stress*, 32(3), 350-362. doi: [10.1002/jts.22362](https://doi.org/10.1002/jts.22362)
- Greenberg Neil, Docherty Mary, Gnanapragasam Sam, Wessely Simon. (2020). Managing mental health challenges faced by healthcare workers during covid-19 pandemic BMJ 2020; 368 :m1211
- Hedeker, D., & Gibbons, R.D. (1997). Application of random-effects pattern-mixture models for missing data in longitudinal studies. *Psychological Methods*, 2(1), 64-78.
<https://doi.org/10.1037/1082-989X.2.1.64>
- Hedeker, D., Gibbons, R., & Waternaux, C. (1999). Sample size estimation for longitudinal designs with attrition: Comparing time-related contrasts between two groups. *Journal of Educational and Behavioral Statistics*, 24, 70-93.
- Held, P., Klassen, B.J., Brennan, M.B., & Zalta, A.K. (2018). Using Prolonged Exposure and Cognitive Processing Therapy to Treat Veterans with Moral Injury-Based PTSD: Two Case Examples. *Cognitive and Behavioral Practice*, 25(3), 377-390. doi: [10.1016/j.cbpra.2017.09.003](https://doi.org/10.1016/j.cbpra.2017.09.003)
- Khantzian, E.J. (1985). The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. *American Journal of Psychiatry*, 142(11), 1259-1264. doi: [10.1176/ajp.142.11.1259](https://doi.org/10.1176/ajp.142.11.1259)
- Koenig, H.G., Ames, D., Youssef, N.A., Oliver, J.P., Volk, F., Teng, E.J., Haynes, K., Erickson, Z.D., Arnold, I., O'Garro, K., & Pearce, M. (2018). The Moral Injury Symptom Scale-Military Version. *Journal of Religion and Health*, 57, 249–265. doi: [10.1007/s10943-017-0531-9](https://doi.org/10.1007/s10943-017-0531-9)

- Kroenke, K. & Spitzer, R.L. (2002). The PHQ-9: a new depression diagnostic and severity measure. *Psychiatric Annals*, 2002. 32(9), 509-515. <https://doi.org/10.3928/0048-5713-20020901-06>
- Kubany, E.S. (1994). A cognitive model of guilt typology in combat-related PTSD. *Journal of Traumatic Stress*, 1994. 7(1), 3-19. <https://doi.org/10.1007/BF02111908>
- Kubany, E.S., Abueg, F.R., Kilauano, W.L., Manke, F.P., & Kaplan, A.S. (1997). Development and validation of the sources of trauma-related guilt survey—war-zone version. *Journal of Traumatic Stress*, 10(2), 235-258. doi: [10.1023/a:1024878112553](https://doi.org/10.1023/a:1024878112553)
- Kubany, E.S., Haynes, S.N., Abueg, F.R., Manke, F.P., Brennan, J.M., & Stahura, C. (1996). Development and validation of the trauma-related guilt inventory (TRGI). *Psychological Assessment*, 1996. 8(4), 428-444. <https://doi.org/10.1037/1040-3590.8.4.428>
- Kubany, E.S., Hill, E.E., Owens, J.A., Iannce-Spencer, C., McCaig, M.A., Tremayne, K.J., & Williams, P.L. (2004). Cognitive trauma therapy for battered women with PTSD (CTT-BW). *Journal of Consulting and Clinical Psychology*, 72(1), 3-18. doi: [10.1037/0022-006X.72.1.3](https://doi.org/10.1037/0022-006X.72.1.3)
- Kubany, E.S., & Watson, S.B. (2003). Guilt: Elaboration of a multidimensional model. *The Psychological Record*, 53, 51-90.
- Lang, A.J., Schnurr, P.P., Jain, S., Raman, R., Walser, R., Bolton, E. Chabot, A., & Benedek, D. (2012). Evaluating transdiagnostic treatment for distress and impairment in veterans: A multi-site randomized controlled trial of Acceptance and Commitment Therapy. *Contemporary Clinical Trials*, 33(1), 116-123. doi: [10.1016/j.cct.2011.08.007](https://doi.org/10.1016/j.cct.2011.08.007)

- Larsen, S.E., Fleming, C.J., & Resick, P.A. (2019). Residual Symptoms Following Empirically Supported Treatment for PTSD. *Psychological Trauma: Theory, Research, Practice, and Policy*, 11(2), 207-215. doi: [10.1037/tra0000384](https://doi.org/10.1037/tra0000384)
- Litz, B.T., Stein, N., Delaney, E., Lebowitz, L., Nash, W. P., Silva, C., & Maguen, S. (2009). Moral injury and moral repair in war veterans: A preliminary model and intervention strategy. *Clinical Psychology Review*, 29(8), 695–706. doi: [10.1016/j.cpr.2009.07.003](https://doi.org/10.1016/j.cpr.2009.07.003)
- Marx, B.P., Foley, K.M., Feinstein, B.A., Wolf, E.J., Kaloupek, D.G., & Keane, T.M. (2010). Combat-related guilt mediates the relations between exposure to combat-related abusive violence and psychiatric diagnoses. *Depression and Anxiety*, 27(3), 287-293. doi: [10.1002/da.20659](https://doi.org/10.1002/da.20659)
- Nash, W.P., Marino Carper, T.L., Mills, M.A., Au, T., Goldsmith, A., Litz, B.T. (2013). Psychometric evaluation of the Moral Injury Events Scale. *Military Medicine*, 178(6), 646-52. doi: [10.7205/MILMED-D-13-00017](https://doi.org/10.7205/MILMED-D-13-00017)
- Nasreddine, Z.S., Phillips, N.A., Bedirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J.L., & Chertkow, H. (2005). The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. *Journal of the American Geriatrics Society*, 53(4), 695-699. doi: [10.1111/j.1532-5415.2005.53221.x](https://doi.org/10.1111/j.1532-5415.2005.53221.x)
- Nishith, P., Nixon, R. D., & Resick, P. A. (2005). Resolution of trauma-related guilt following treatment of PTSD in female rape victims: A result of cognitive processing therapy targeting comorbid depression? *Journal of Affective Disorders*, 86(2-3), 259–265. <https://doi.org/10.1016/j.jad.2005.02.013>

- Norman, S.B., Allard, C.B., Browne, K.C., Capone, C., Davis, B.C., & Kubany, E. (2019). *Trauma Informed Guilt Reduction Therapy: Treating Guilt and Shame Resulting from Trauma and Moral Injury*. Academic Press.
- Norman, S. B., Haller, M., Kim, H. M., Allard, C. B., Porter, K. E., Stein, M. B., Venners, M.R., Authier, C.C., Rauch, S. A. M., & Progress Team (2018). Trauma related guilt cognitions partially mediate the relationship between PTSD symptom severity and functioning among returning combat veterans. *Journal of Psychiatric Research*, 100, 56-62. <http://doi.org/10.1016/j.jpsychires.2018.02.003>
- Norman, S.B., Wilkins, K.C., Myers, U.S., & Allard, C.B. (2014). Trauma informed guilt reduction therapy with combat veterans. *Cognitive and Behavioral Practice*, 21, 78-88. <https://doi.org/10.1016/j.cbpra.2013.08.001>
- Øktedalen, T., Hagtvet, K.A., Hoffart, A. Langkass, T.F., & Smucker, M. (2014). The Trauma Related Shame Inventory: Measuring Trauma-Related Shame Among Patients with PTSD. *Journal of Psychopathology and Behavior Assessment*, 36, 600–615. <https://doi.org/10.1007/s10862-014-9422-5>
- Pittman, J.O.E., Floto, E., Lindamer, L., Baker, D.G., Lohr, J.B., & Afari, N. (2017). VA eScreening program: Technology to improve care for post-9/11 veterans. *Psychological Services*, 14(1), 23-33. doi: 10.1037/ser0000125
- Posner, K., Brent, D., Lucas, C., Gould, M., Stanley, B., Brown, G., Fisher, P., Zelazny, J., Burke, A., Oquendo, M., & Mann, J. (2008). Columbia-Suicide Severity Rating Scale (C-SSRS). The Research Foundation for Mental Hygiene, Inc: New York, NY.
- Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., & Mann, J. J. (2011). The Columbia-

- Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. *The American journal of psychiatry*, 168(12), 1266–1277. <https://doi.org/10.1176/appi.ajp.2011.10111704>
- Resick, P. A., Nishith, P., Weaver, T. L., Astin, M. C., & Feuer, C. A. (2002). A comparison of cognitive-processing therapy with prolonged exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape victims. *Journal of Consulting and Clinical Psychology*, 70, 867-879. doi: [10.1037//0022-006x.70.4.867](https://doi.org/10.1037//0022-006x.70.4.867)
- Robinson, S. M., Sobell, L. C., Sobell, M. B., & Leo, G. I. (2014). Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use. *Psychology of Addictive Behaviors*, 28(1), 154–162. <https://doi-org.revproxy.brown.edu/10.1037/a0030992>
- Room, R. (1990). Measuring alcohol consumption in the United States: methods and rationales. In L. Kozlowski, H.M. Annis, H.D. Cappell, F.B. Glaser, M.S. Goodstadt, Y. Israel, H. Kalant, E.M. Sellers, & E.R. Vingilis (Eds.), *Research advances in alcohol and drug problems*, vol. 10, pp. 39-80. Plenum Press.
- Shea , M.T., Bernardy, N., Howard, J., Key, F., & Lambert, J. (2003). Present Centered Therapy Manual. Unpublished manuscript.
- Shea, M. T., Krupnick, J. L., Belsher, B. E., & Schnurr, P. P. (2020). Non-trauma focused psychotherapies for the treatment of PTSD: A descriptive review. *Current Treatment Options in Psychiatry*, published online. DOI [10.1007/s40501-020-00214-y](https://doi.org/10.1007/s40501-020-00214-y)
- Sobell, L.C. & Sobell, M.B. (1992). Timeline follow-back: a technique for assessing self-reported alcohol consumption. In R.Z. Litten & J.P. Allen (Eds). *Measuring alcohol consumption*, pp 41-72. Humana Press. https://doi.org/10.1007/978-1-4612-0357-5_3

- Spitzer, R.L., Kroenke, K., Williams, J.B.W., and the Patient Health Questionnaire Primary Care Study Group. (1999). Validation and Utility of a Self-report Version of PRIME-MD: The PHQ Primary Care Study. *JAMA*, 282(18),1737–1744. doi:10.1001/jama.282.18.1737
- Tangney, J.P., Stuewig, J., & Mashek, D.J. (2007). Moral emotions and moral behavior. *Annual Review of Psychology*, 58, 345-372. doi: [10.1146/annurev.psych.56.091103.070145](https://doi.org/10.1146/annurev.psych.56.091103.070145)
- Weathers, F. W., Bovin, M. J., Lee, D. J., Sloan, D. M., Schnurr, P. P., Kaloupek, D. G., . . . & Marx, B. P. (2018). The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military Veterans. *Psychological Assessment*, 30, 383-395. doi:10.1037/pas0000486
- Weathers, F.W., Litz, B.T., Keane, T.M., Palmieri, P.A., Marx, B.P., & Schnurr, P.P. (2013). The PTSD Checklist for *DSM-5* (PCL-5). Scale available from the National Center for PTSD at www.ptsd.va.gov.
- Weiss, R., Hufford, C., Najavits, L., and Shaw, S. (1995). *Weekly substance use inventory*. Unpublished measure, Harvard University Medical School, Boston, MA.
- WHOQOL Group. (1998). Development of the World Health Organization WHOQOL-BREF quality of life assessment. *Psychol Med*, 28(3), 551-558. DOI: [10.1017/s0033291798006667](https://doi.org/10.1017/s0033291798006667)
- Wilkins, K. C., Myers, U. S., Goldsmith, A. A., Buzzella, B., & Norman, S. B. (2013). High-risk behaviors in Iraq and Afghanistan veterans: The role of trauma-related guilt. Presented at the Anxiety and Depression Association of America Annual Conference, La Jolla, CA.

Table 1. TrIGR Modules

Module	Description
1. Psycho-Education (2 sessions)	• Present psychoeducation on common reactions to trauma, flight/flight/freeze response, definitions of guilt and shame • Present psychoeducation on NAGS Model, role of guilt in PTSD and other problems, and common types of guilt following a traumatic event
2. Guilt Debrief (2 sessions)	• Participant completes Attitudes About Guilt Survey (AAGS) • Identify participant's guilt cognitions • Evaluate each of four guilt-related beliefs (foreseeability/preventability, justification for actions taken, causal responsibility, violation of values/wrongdoing) • Identify possible function of holding on to guilt (e.g., honoring someone's memory, punishing oneself)
3. Identifying Values (1 session)	• Identification of values across ten life domains (career, family, etc.) • Identify values that may have been violated during the traumatic event • Examine if/how participant is currently living according to values
4. Value-Driven Growth (1 session)	• Assist participant in generating goals that are in accordance with values • Troubleshoot obstacles, review goal monitoring strategies • Make commitment to behave in accordance with values

Acknowledgements

This study was made possible by funding from the Department of Defense (W81XWH-15-1-0330; PI: Norman and W81XWH-15-1-0331; PI: Capone; ClinicalTrials.gov identifier: NCT02512445).